

Data Set Name: adm.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|--------------|------|-----|------------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | DISCPTST | Char | 1 | \$X1592X. | \$1. | Pt Status at Discharge |
| 5 | PHSPREAS | Char | 2 | \$X55670X. | \$2. | Prim Reason for Re-Admit |
| 6 | ADMISPEC | Char | 50 | \$50. | \$50. | Primary Reason Other Spec |
| 7 | REASGVHD | Char | 1 | \$X4602X. | \$1. | GVHD |
| 8 | REASRLPS | Char | 1 | \$X4602X. | \$1. | Relapse/Progression |
| 9 | REASGF | Char | 1 | \$X4602X. | \$1. | Graft Failure |
| 10 | REASINF | Char | 1 | \$X4602X. | \$1. | Infection |
| 11 | REASFVR | Char | 1 | \$X4602X. | \$1. | Fever |
| 12 | REASSZR | Char | 1 | \$X4602X. | \$1. | Seizure |
| 13 | REASGIBL | Char | 1 | \$X4602X. | \$1. | Bleeding |
| 14 | REASDRH | Char | 1 | \$X4602X. | \$1. | Diarrhea |
| 15 | REASNV | Char | 1 | \$X4602X. | \$1. | Nausea/Vomiting |
| 16 | REASORGF | Char | 1 | \$X4602X. | \$1. | Organ Failure |
| 17 | ADM3SPEC | Char | 50 | \$50. | \$50. | Specify Organ |
| 18 | REASTRAM | Char | 1 | \$X4602X. | \$1. | Trauma |
| 19 | REASPSYC | Char | 1 | \$X4602X. | \$1. | Psychiatric |
| 20 | REASMALG | Char | 1 | \$X4602X. | \$1. | Secondary Malignancy |
| 21 | REASPROC | Char | 1 | \$X4602X. | \$1. | Procedure/Treatment |
| 22 | REASTRMB | Char | 1 | \$X4602X. | \$1. | Thrombosis/Embolism |
| 23 | REASOTHR | Char | 1 | \$X4602X. | \$1. | Other |
| 24 | ADM2SPEC | Char | 50 | \$50. | \$50. | Other Reason Specify |
| 25 | ADMCENTR | Char | 1 | \$X1651X. | \$1. | Re-Admission Center |
| 26 | ADMITDT_DAYS | Num | 8 | | | Date of Admission (recode: number of days after consent) |
| 27 | DISCHDT_DAYS | Num | 8 | | | Date of Discharge (recode: number of days after consent) |

Data Set Name: ae.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|------------|----------|----------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | ADVENT | Char | 35 | \$35. | \$35. | Event description |
| 5 | AVWGHTKG | Num | 8 | 7.1 | 7.1 | Weight in kilograms |
| 6 | AVEXPECT | Char | 1 | \$X1457X. | \$1. | Expected |
| 7 | AVEVENT | Char | 1 | \$X4680X. | \$1. | Severity of event |
| 8 | AVRELAT | Char | 1 | \$X4681X. | \$1. | Relationship to study pro |
| 9 | AVETIOL | Char | 1 | \$X10839X. | \$1. | Alternative etiology |
| 10 | AVEFFECT | Char | 1 | \$X10840X. | \$1. | Effect on therapy/interven |
| 11 | AVOUTCOM | Char | 1 | \$X10841X. | \$1. | Outcome of the event |
| 12 | AVASSOCI | Char | 1 | \$X4685X. | \$1. | Event associated with |
| 13 | SEMEDHXS | Char | 1 | \$X1457X. | \$1. | Relevant past med hx |
| 14 | RCVSP | Char | 1 | \$X1457X. | \$1. | Receiving study products |
| 15 | SPNAME1 | Char | 20 | \$20. | \$20. | Study product name 1 |
| 16 | SP1DOSE | Char | 12 | \$12. | \$12. | Study product 1 dose |
| 17 | SP1ROUTE | Char | 10 | \$10. | \$10. | Study product 1 route |
| 18 | SP1SCHED | Char | 12 | \$12. | \$12. | Study product 1 schedule |
| 19 | SP1REASO | Char | 25 | \$25. | \$25. | Study product 1 reason |
| 20 | SPNAME2 | Char | 20 | \$20. | \$20. | Study product name 2 |
| 21 | SP2DOSE | Char | 12 | \$12. | \$12. | Study product 2 dose |
| 22 | SP2ROUTE | Char | 10 | \$10. | \$10. | Study product 2 route |
| 23 | SP2SCHED | Char | 12 | \$12. | \$12. | Study product 2 schedule |
| 24 | SP2REASO | Char | 25 | \$25. | \$25. | Study product 2 reason |
| 25 | SPNAME3 | Char | 20 | \$20. | \$20. | Study product name 3 |
| 26 | SP3DOSE | Char | 12 | \$12. | \$12. | Study product 3 dose |
| 27 | SP3ROUTE | Char | 10 | \$10. | \$10. | Study product 3 route |
| 28 | SP3SCHED | Char | 12 | \$12. | \$12. | Study product 3 schedule |
| 29 | SP3REASO | Char | 25 | \$25. | \$25. | Study product 3 reason |
| 30 | RCVCONMD | Char | 1 | \$X1457X. | \$1. | Receiving con meds |
| 31 | CONMED1 | Char | 30 | \$30. | \$30. | Concomitant Medication 1 |
| 32 | CM1DOSE | Char | 20 | \$20. | \$20. | Con med 1 dose/route/sche |
| 33 | CM1INDIC | Char | 1 | \$X4687X. | \$1. | Con med 1 indication |
| 34 | CONMED2 | Char | 30 | \$30. | \$30. | Concomitant Medication 2 |
| 35 | CM2DOSE | Char | 20 | \$20. | \$20. | Con med 2 dose/route/sche |
| 36 | CM2INDIC | Char | 1 | \$X4687X. | \$1. | Con med 2 indication |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|-----------|----------|---------------------------|
| 37 | CONMED3 | Char | 30 | \$30. | \$30. | Concomitant Medication 3 |
| 38 | CM3DOSE | Char | 20 | \$20. | \$20. | Con med 3 dose/route/sche |
| 39 | CM3INDIC | Char | 1 | \$X4687X. | \$1. | Con med 3 indication |
| 40 | CONMED4 | Char | 30 | \$30. | \$30. | Concomitant Medication 4 |
| 41 | CM4DOSE | Char | 20 | \$20. | \$20. | Con med 4 dose/route/sche |
| 42 | CM4INDIC | Char | 1 | \$X4687X. | \$1. | Con med 4 indication |
| 43 | CONMED5 | Char | 30 | \$30. | \$30. | Concomitant Medication 5 |
| 44 | CM5DOSE | Char | 20 | \$20. | \$20. | Con med 5 dose/route/sche |
| 45 | CM5INDIC | Char | 1 | \$X4687X. | \$1. | Con med 5 indication |
| 46 | CONMED6 | Char | 30 | \$30. | \$30. | Concomitant Medication 6 |
| 47 | CM6DOSE | Char | 20 | \$20. | \$20. | Con med 6 dose/route/sche |
| 48 | CM6INDIC | Char | 1 | \$X4687X. | \$1. | Con med 6 indication |
| 49 | CONMED7 | Char | 30 | \$30. | \$30. | Concomitant Medication 7 |
| 50 | CM7DOSE | Char | 20 | \$20. | \$20. | Con med 7 dose/route/sche |
| 51 | CM7INDIC | Char | 1 | \$X4687X. | \$1. | Con med 7 indication |
| 52 | CONMED8 | Char | 30 | \$30. | \$30. | Concomitant Medication 8 |
| 53 | CM8DOSE | Char | 20 | \$20. | \$20. | Con med 8 dose/route/sche |
| 54 | CM8INDIC | Char | 1 | \$X4687X. | \$1. | Con med 8 indication |
| 55 | CONMED9 | Char | 30 | \$30. | \$30. | Concomitant Medication 9 |
| 56 | CM9DOSE | Char | 20 | \$20. | \$20. | Con med 9 dose/route/sche |
| 57 | CM9INDIC | Char | 1 | \$X4687X. | \$1. | Con med 9 indication |
| 58 | CONMED10 | Char | 30 | \$30. | \$30. | Concomitant medication 10 |
| 59 | CM10DOSE | Char | 20 | \$20. | \$20. | Con med 10 dose/route/sch |
| 60 | CM10INDI | Char | 1 | \$X4687X. | \$1. | Con med 10 indication |
| 61 | CONMED11 | Char | 30 | \$30. | \$30. | Concomitant medication 11 |
| 62 | CM11DOSE | Char | 20 | \$20. | \$20. | Con med 11 dose/route/sch |
| 63 | CM11INDI | Char | 1 | \$X4687X. | \$1. | Con med 11 indication |
| 64 | CONMED12 | Char | 30 | \$30. | \$30. | Concomitant medication 12 |
| 65 | CM12DOSE | Char | 20 | \$20. | \$20. | Con med 12 dose/route/sch |
| 66 | CM12INDI | Char | 1 | \$X4687X. | \$1. | Con med 12 indication |
| 67 | CONMED13 | Char | 30 | \$30. | \$30. | Concomitant medication 13 |
| 68 | CM13DOSE | Char | 20 | \$20. | \$20. | Con med 13 dose/route/sch |
| 69 | CM13INDI | Char | 1 | \$X4687X. | \$1. | Con med 13 indication |
| 70 | CONMED14 | Char | 30 | \$30. | \$30. | Concomitant medication 14 |
| 71 | CM14DOSE | Char | 20 | \$20. | \$20. | Con med 14 dose/route/sch |
| 72 | CM14INDI | Char | 1 | \$X4687X. | \$1. | Con med 14 indication |
| 73 | CONMED15 | Char | 30 | \$30. | \$30. | Concomitant medication 15 |
| 74 | CM15DOSE | Char | 20 | \$20. | \$20. | Con med 15 dose/route/sch |
| 75 | CM15INDI | Char | 1 | \$X4687X. | \$1. | Con med 15 indication |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|-----------|----------|---------------------------|
| 76 | CONMED16 | Char | 30 | \$30. | \$30. | Concomitant medication 16 |
| 77 | CM16DOSE | Char | 20 | \$20. | \$20. | Con med 16 dose/route/sch |
| 78 | CM16INDI | Char | 1 | \$X4687X. | \$1. | Con med 16 indication |
| 79 | CONMED17 | Char | 30 | \$30. | \$30. | Concomitant medication 17 |
| 80 | CM17DOSE | Char | 20 | \$20. | \$20. | Con med 17 dose/route/sch |
| 81 | CM17INDI | Char | 1 | \$X4687X. | \$1. | Con med 17 indication |
| 82 | CONMED18 | Char | 30 | \$30. | \$30. | Concomitant medication 18 |
| 83 | CM18DOSE | Char | 20 | \$20. | \$20. | Con med 18 dose/route/sch |
| 84 | CM18INDI | Char | 1 | \$X4687X. | \$1. | Con med 18 indication |
| 85 | CONMED19 | Char | 30 | \$30. | \$30. | Concomitant medication 19 |
| 86 | CM19DOSE | Char | 20 | \$20. | \$20. | Con med 19 dose/route/sch |
| 87 | CM19INDI | Char | 1 | \$X4687X. | \$1. | Con med 19 indication |
| 88 | CONMED20 | Char | 30 | \$30. | \$30. | Concomitant medication 20 |
| 89 | CM20DOSE | Char | 20 | \$20. | \$20. | Con med 20 dose/route/sch |
| 90 | CM20INDI | Char | 1 | \$X4687X. | \$1. | Con med 20 indication |
| 91 | CONMED21 | Char | 30 | \$30. | \$30. | Concomitant medication 21 |
| 92 | CM21DOSE | Char | 20 | \$20. | \$20. | Con med 21 dose/route/sch |
| 93 | CM21INDI | Char | 1 | \$X4687X. | \$1. | Con med 21 indication |
| 94 | CONMED22 | Char | 30 | \$30. | \$30. | Concomitant medication 22 |
| 95 | CM22DOSE | Char | 20 | \$20. | \$20. | Con med 22 dose/route/sch |
| 96 | CM22INDI | Char | 1 | \$X4687X. | \$1. | Con med 22 indications |
| 97 | CONMED23 | Char | 30 | \$30. | \$30. | Concomitant medication 23 |
| 98 | CM23DOSE | Char | 20 | \$20. | \$20. | Con med 23 dose/route/sch |
| 99 | CM23INDI | Char | 1 | \$X4687X. | \$1. | Con med 23 indication |
| 100 | CONMED24 | Char | 30 | \$30. | \$30. | Concomitant medication 24 |
| 101 | CM24DOSE | Char | 20 | \$20. | \$20. | Con med 24 dose/route/sch |
| 102 | CM24INDI | Char | 1 | \$X4687X. | \$1. | Con med 24 indication |
| 103 | CONMED25 | Char | 30 | \$30. | \$30. | Concomitant medication 25 |
| 104 | CM25DOSE | Char | 20 | \$20. | \$20. | Con med 25 dose/route/sch |
| 105 | CM25INDI | Char | 1 | \$X4687X. | \$1. | Con med 25 indication |
| 106 | LABTSTPF | Char | 1 | \$X1457X. | \$1. | Lab tests performed |
| 107 | ADLTST1 | Char | 20 | \$20. | \$20. | Laboratory test 1 |
| 108 | ADL1RES | Char | 10 | \$10. | \$10. | Lab test 1 result |
| 109 | ADL1NORG | Char | 15 | \$15. | \$15. | Lab test 1 normal range |
| 110 | ADL1PRVL | Char | 10 | \$10. | \$10. | Lab test 1 previous value |
| 111 | ADLTST2 | Char | 20 | \$20. | \$20. | Laboratory test 2 |
| 112 | ADL2RES | Char | 10 | \$10. | \$10. | Lab test 2 result |
| 113 | ADL2NORG | Char | 15 | \$15. | \$15. | Lab test 2 normal range |
| 114 | ADL2PRVL | Char | 10 | \$10. | \$10. | Lab test 2 previous value |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|-----------|----------|---------------------------|
| 115 | ADLTST3 | Char | 20 | \$20. | \$20. | Laboratory test 3 |
| 116 | ADL3RES | Char | 10 | \$10. | \$10. | Lab test 3 result |
| 117 | ADL3NORG | Char | 15 | \$15. | \$15. | Lab test 3 normal range |
| 118 | ADL3PRVL | Char | 10 | \$10. | \$10. | Lab test 3 previous value |
| 119 | ADLTST4 | Char | 20 | \$20. | \$20. | Laboratory test 4 |
| 120 | ADL4RES | Char | 10 | \$10. | \$10. | Lab test 4 result |
| 121 | ADL4NORG | Char | 15 | \$15. | \$15. | Lab test 4 normal range |
| 122 | ADL4PRVL | Char | 10 | \$10. | \$10. | Lab test 4 previous value |
| 123 | ADLTST5 | Char | 20 | \$20. | \$20. | Laboratory test 5 |
| 124 | ADL5RES | Char | 10 | \$10. | \$10. | Lab test 5 result |
| 125 | ADL5NORG | Char | 15 | \$15. | \$15. | Lab test 5 normal range |
| 126 | ADL5PRVL | Char | 10 | \$10. | \$10. | Lab test 5 previous value |
| 127 | ADLTST6 | Char | 20 | \$20. | \$20. | Laboratory test 6 |
| 128 | ADL6RES | Char | 10 | \$10. | \$10. | Lab test 6 result |
| 129 | ADL6NORG | Char | 15 | \$15. | \$15. | Lab test 6 normal range |
| 130 | ADL6PRVL | Char | 10 | \$10. | \$10. | Lab test 6 previous value |
| 131 | ADLTST7 | Char | 20 | \$20. | \$20. | Laboratory test 7 |
| 132 | ADL7RES | Char | 10 | \$10. | \$10. | Lab test 7 result |
| 133 | ADL7NORG | Char | 15 | \$15. | \$15. | Lab test 7 normal range |
| 134 | ADL7PRVL | Char | 10 | \$10. | \$10. | Lab test 7 previous value |
| 135 | ADLTST8 | Char | 20 | \$20. | \$20. | Laboratory test 8 |
| 136 | ADL8RES | Char | 10 | \$10. | \$10. | Lab test 8 result |
| 137 | ADL8NORG | Char | 15 | \$15. | \$15. | Lab test 8 normal range |
| 138 | ADL8PRVL | Char | 10 | \$10. | \$10. | Lab test 8 previous value |
| 139 | ADLTST9 | Char | 20 | \$20. | \$20. | Laboratory test 9 |
| 140 | ADL9RES | Char | 10 | \$10. | \$10. | Lab test 9 result |
| 141 | ADL9NORG | Char | 15 | \$15. | \$15. | Lab test 9 normal range |
| 142 | ADL9PRVL | Char | 10 | \$10. | \$10. | Lab test 9 previous value |
| 143 | ADLTST10 | Char | 20 | \$20. | \$20. | Laboratory test 10 |
| 144 | ADL10RES | Char | 10 | \$10. | \$10. | Lab test 10 result |
| 145 | ADL10NRG | Char | 15 | \$15. | \$15. | Lab test 10 normal range |
| 146 | ADL10PVL | Char | 10 | \$10. | \$10. | Lab test 10 prev value |
| 147 | DXSTPF | Char | 1 | \$X1457X. | \$1. | Diagnostic tests perform |
| 148 | ADDTS1 | Char | 20 | \$20. | \$20. | Diagnostic test 1 |
| 149 | ADDTS2 | Char | 20 | \$20. | \$20. | Diagnostic test 2 |
| 150 | ADDTS3 | Char | 20 | \$20. | \$20. | Diagnostic test 3 |
| 151 | ADDTS4 | Char | 20 | \$20. | \$20. | Diagnostic test 4 |
| 152 | ADDTS5 | Char | 20 | \$20. | \$20. | Diagnostic test 5 |
| 153 | ADDTS6 | Char | 20 | \$20. | \$20. | Diagnostic test 6 |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|------------|----------|--|
| 154 | ADDTS7 | Char | 20 | \$20. | \$20. | Diagnostic test 7 |
| 155 | ADDTS8 | Char | 20 | \$20. | \$20. | Diagnostic test 8 |
| 156 | ADDTS9 | Char | 20 | \$20. | \$20. | Diagnostic test 9 |
| 157 | AEREVIEW | Char | 1 | \$X1457X. | \$1. | Adverse event reviewed |
| 158 | AMMMEVDS | Char | 35 | \$35. | \$35. | MM Event Description |
| 159 | CTCAEGRD | Char | 1 | \$X30900X. | \$1. | CTCAE Grade of Event |
| 160 | ADVDATE_DAYS | Num | 8 | | | Date of Onset (recode: number of days after consent) |
| 161 | AVAWARDT_DAYS | Num | 8 | | | Site awareness date (recode: number of days after consent) |
| 162 | AVRESDT_DAYS | Num | 8 | | | Date of resolution (recode: number of days after consent) |
| 163 | SEISUBDT_DAYS | Num | 8 | | | Initial submit date (recode: number of days after consent) |
| 164 | SP1STDT_DAYS | Num | 8 | | | Study product 1 start dte (recode: number of days after consent) |
| 165 | SP1SPDT_DAYS | Num | 8 | | | Study product 1 stop date (recode: number of days after consent) |
| 166 | SP2STDT_DAYS | Num | 8 | | | Study product 2 start dte (recode: number of days after consent) |
| 167 | SP2SPDT_DAYS | Num | 8 | | | Study product 2 stop date (recode: number of days after consent) |
| 168 | SP3STDT_DAYS | Num | 8 | | | Study product 3 start dte (recode: number of days after consent) |
| 169 | SP3SPDT_DAYS | Num | 8 | | | Study product 3 stop date (recode: number of days after consent) |
| 170 | CM1STDT_DAYS | Num | 8 | | | Con med 1 start date (recode: number of days after consent) |
| 171 | CM1SPDT_DAYS | Num | 8 | | | Con med 1 stop date (recode: number of days after consent) |
| 172 | CM2STDT_DAYS | Num | 8 | | | Con med 2 start date (recode: number of days after consent) |
| 173 | CM2SPDT_DAYS | Num | 8 | | | Con med 2 stop date (recode: number of days after consent) |
| 174 | CM3STDT_DAYS | Num | 8 | | | Con med 3 start date (recode: number of days after consent) |
| 175 | CM3SPDT_DAYS | Num | 8 | | | Con med 3 stop date (recode: number of days after consent) |
| 176 | CM4STDT_DAYS | Num | 8 | | | Con med 4 start date (recode: number of days after consent) |
| 177 | CM4SPDT_DAYS | Num | 8 | | | Con med 4 stop date (recode: number of days after consent) |
| 178 | CM5STDT_DAYS | Num | 8 | | | Con med 5 start date (recode: number of days after consent) |
| 179 | CM5SPDT_DAYS | Num | 8 | | | Con med 5 stop date (recode: number of days after consent) |
| 180 | CM6STDT_DAYS | Num | 8 | | | Con med 6 start date (recode: number of days after consent) |
| 181 | CM6SPDT_DAYS | Num | 8 | | | Con med 6 stop date (recode: number of days after consent) |
| 182 | CM7STDT_DAYS | Num | 8 | | | Con med 7 start date (recode: number of days after consent) |
| 183 | CM7SPDT_DAYS | Num | 8 | | | Con med 7 stop date (recode: number of days after consent) |
| 184 | CM8STDT_DAYS | Num | 8 | | | Con med 8 start date (recode: number of days after consent) |
| 185 | CM8SPDT_DAYS | Num | 8 | | | Con med 8 stop date (recode: number of days after consent) |
| 186 | CM9STDT_DAYS | Num | 8 | | | Con med 9 start date (recode: number of days after consent) |
| 187 | CM9SPDT_DAYS | Num | 8 | | | Con med 9 stop date (recode: number of days after consent) |
| 188 | CM10STDT_DAYS | Num | 8 | | | Con med 10 start date (recode: number of days after consent) |
| 189 | CM10SPDT_DAYS | Num | 8 | | | Con med 10 stop date (recode: number of days after consent) |
| 190 | CM11STDT_DAYS | Num | 8 | | | Con med 11 start date (recode: number of days after consent) |
| 191 | CM11SPDT_DAYS | Num | 8 | | | Con med 11 stop date (recode: number of days after consent) |
| 192 | CM12STDT_DAYS | Num | 8 | | | Con med 12 start date (recode: number of days after consent) |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|--------|----------|--|
| 193 | CM12SPDT_DAYS | Num | 8 | | | Con med 12 stop date (recode: number of days after consent) |
| 194 | CM13STDT_DAYS | Num | 8 | | | Con med 13 start date (recode: number of days after consent) |
| 195 | CM13SPDT_DAYS | Num | 8 | | | Con med 13 stop date (recode: number of days after consent) |
| 196 | CM14STDT_DAYS | Num | 8 | | | Con med 14 start date (recode: number of days after consent) |
| 197 | CM14SPDT_DAYS | Num | 8 | | | Con med 14 stop date (recode: number of days after consent) |
| 198 | CM15STDT_DAYS | Num | 8 | | | Con med 15 start date (recode: number of days after consent) |
| 199 | CM15SPDT_DAYS | Num | 8 | | | Con med 15 stop date (recode: number of days after consent) |
| 200 | CM16STDT_DAYS | Num | 8 | | | Con med 16 start date (recode: number of days after consent) |
| 201 | CM16SPDT_DAYS | Num | 8 | | | Con med 16 stop date (recode: number of days after consent) |
| 202 | CM17STDT_DAYS | Num | 8 | | | Con med 17 start date (recode: number of days after consent) |
| 203 | CM17SPDT_DAYS | Num | 8 | | | Con med 17 stop date (recode: number of days after consent) |
| 204 | CM18STDT_DAYS | Num | 8 | | | Con med 18 start date (recode: number of days after consent) |
| 205 | CM18SPDT_DAYS | Num | 8 | | | Con med 18 stop date (recode: number of days after consent) |
| 206 | CM19STDT_DAYS | Num | 8 | | | Con med 19 start date (recode: number of days after consent) |
| 207 | CM19SPDT_DAYS | Num | 8 | | | Con med 19 stop date (recode: number of days after consent) |
| 208 | CM20STDT_DAYS | Num | 8 | | | Con med 20 start date (recode: number of days after consent) |
| 209 | CM20SPDT_DAYS | Num | 8 | | | Con med 20 stop date (recode: number of days after consent) |
| 210 | CM21STDT_DAYS | Num | 8 | | | Con med 21 start date (recode: number of days after consent) |
| 211 | CM21SPDT_DAYS | Num | 8 | | | Con med 21 stop date (recode: number of days after consent) |
| 212 | CM22STDT_DAYS | Num | 8 | | | Con med 22 start date (recode: number of days after consent) |
| 213 | CM22SPDT_DAYS | Num | 8 | | | Con med 22 stop date (recode: number of days after consent) |
| 214 | CM23STDT_DAYS | Num | 8 | | | Con med 23 start date (recode: number of days after consent) |
| 215 | CM23SPDT_DAYS | Num | 8 | | | Con med 23 stop date (recode: number of days after consent) |
| 216 | CM24STDT_DAYS | Num | 8 | | | Con med 24 start date (recode: number of days after consent) |
| 217 | CM24SPDT_DAYS | Num | 8 | | | Con med 24 stop date (recode: number of days after consent) |
| 218 | CM25STDT_DAYS | Num | 8 | | | Con med 25 start date (recode: number of days after consent) |
| 219 | CM25SPDT_DAYS | Num | 8 | | | Con med 25 stop date (recode: number of days after consent) |
| 220 | ADL1CD_DAYS | Num | 8 | | | Lab test 1 collection dt (recode: number of days after consent) |
| 221 | ADL1PCD_DAYS | Num | 8 | | | Lab test 1 prev coll date (recode: number of days after consent) |
| 222 | ADL2CD_DAYS | Num | 8 | | | Lab test 2 collection dt (recode: number of days after consent) |
| 223 | ADL2PCD_DAYS | Num | 8 | | | Lab test 2 prev coll date (recode: number of days after consent) |
| 224 | ADL3CD_DAYS | Num | 8 | | | Lab test 3 collection dt (recode: number of days after consent) |
| 225 | ADL3PCD_DAYS | Num | 8 | | | Lab test 3 prev coll date (recode: number of days after consent) |
| 226 | ADL4CD_DAYS | Num | 8 | | | Lab test 4 collection dt (recode: number of days after consent) |
| 227 | ADL4PCD_DAYS | Num | 8 | | | Lab test 4 prev coll date (recode: number of days after consent) |
| 228 | ADL5CD_DAYS | Num | 8 | | | Lab test 5 collection dt (recode: number of days after consent) |
| 229 | ADL5PCD_DAYS | Num | 8 | | | Lab test 5 prev coll date (recode: number of days after consent) |
| 230 | ADL6CD_DAYS | Num | 8 | | | Lab test 6 collection dte (recode: number of days after consent) |
| 231 | ADL6PCD_DAYS | Num | 8 | | | Lab test 6 prev coll date (recode: number of days after consent) |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------------|------|-----|--------|----------|--|
| 232 | ADL7CD_DAYS | Num | 8 | | | Lab test 7 collection dte (recode: number of days after consent) |
| 233 | ADL7PCD_DAYS | Num | 8 | | | Lab test 7 prev coll date (recode: number of days after consent) |
| 234 | ADL8CD_DAYS | Num | 8 | | | Lab test 8 collection dte (recode: number of days after consent) |
| 235 | ADL8PCD_DAYS | Num | 8 | | | Lab test 8 prev coll date (recode: number of days after consent) |
| 236 | ADL9CD_DAYS | Num | 8 | | | Lab test 9 collection dte (recode: number of days after consent) |
| 237 | ADL9PCD_DAYS | Num | 8 | | | Lab test 9 prev coll date (recode: number of days after consent) |
| 238 | ADL10CD_DAYS | Num | 8 | | | Lab test 10 collection dt (recode: number of days after consent) |
| 239 | ADL10PCD_DAYS | Num | 8 | | | Lab test 10 prev coll dte (recode: number of days after consent) |
| 240 | AD1DTPDAT_DAYS | Num | 8 | | | Date of diag test 1 (recode: number of days after consent) |
| 241 | AD2DTPDAT_DAYS | Num | 8 | | | Date of diag test 2 (recode: number of days after consent) |
| 242 | AD3DTPDAT_DAYS | Num | 8 | | | Date of diag test 3 (recode: number of days after consent) |
| 243 | AD4DTPDAT_DAYS | Num | 8 | | | Date of diag test 4 (recode: number of days after consent) |
| 244 | AD5DTPDAT_DAYS | Num | 8 | | | Date of diag test 5 (recode: number of days after consent) |
| 245 | AD6DTPDAT_DAYS | Num | 8 | | | Date of diag test 6 (recode: number of days after consent) |
| 246 | AD7DTPDAT_DAYS | Num | 8 | | | Date of diag test 7 (recode: number of days after consent) |
| 247 | AD8DTPDAT_DAYS | Num | 8 | | | Date of diag test 8 (recode: number of days after consent) |
| 248 | AD9DTPDAT_DAYS | Num | 8 | | | Date of diag test 9 (recode: number of days after consent) |
| 249 | ARFREVDT_DAYS | Num | 8 | | | Review form review date (recode: number of days after consent) |

Data Set Name: cr9.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|--------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | CR9PATWT | Num | 8 | 7.1 | 7.1 | Patient's Weight |
| 6 | CR9PTIBW | Num | 8 | 7.1 | 7.1 | Patient's IBW |
| 7 | CR9PTBSA | Num | 8 | 6.2 | 6.2 | Patient's BSA |
| 8 | CR9ATG1D | Num | 8 | 4. | 4. | ATG Dose 1 |
| 9 | CR9ATG2D | Num | 8 | 4. | 4. | ATG Dose 2 |
| 10 | CR9ATG3D | Num | 8 | 4. | 4. | ATG Dose 3 |
| 11 | CR9FLU1D | Num | 8 | 8.2 | 8.2 | Fludarabine Dose 1 |
| 12 | CR9FLU2D | Num | 8 | 8.2 | 8.2 | Fludarabine Dose 2 |
| 13 | CR9FLU3D | Num | 8 | 8.2 | 8.2 | Fludarabine Dose 3 |
| 14 | CR9FLU4D | Num | 8 | 8.2 | 8.2 | Fludarabine Dose 4 |
| 15 | CR9FLU5D | Num | 8 | 8.2 | 8.2 | Fludarabine Dose 5 |
| 16 | CR9CYC1D | Num | 8 | 9.1 | 9.1 | Cyclophosphamide Dose 1 |
| 17 | CR9CYC2D | Num | 8 | 9.1 | 9.1 | Cyclophosphamide Dose 2 |
| 18 | CR9CYC3D | Num | 8 | 9.1 | 9.1 | Cyclophosphamide Dose 3 |
| 19 | CR9CYC4D | Num | 8 | 9.1 | 9.1 | Cyclophosphamide Dose 4 |
| 20 | CR9TBIDS | Num | 8 | 4. | 4. | Total Body Irradiation |
| 21 | CR9BSADT_DAYS | Num | 8 | | | Patient's BSA Date (recode: number of days after consent) |
| 22 | CR9PWTDT_DAYS | Num | 8 | | | Patient's Weight Date (recode: number of days after consent) |
| 23 | CR9AT1DT_DAYS | Num | 8 | | | ATG Dose 1 Date (recode: number of days after consent) |
| 24 | CR9AT2DT_DAYS | Num | 8 | | | ATG Dose 2 Date (recode: number of days after consent) |
| 25 | CR9AT3DT_DAYS | Num | 8 | | | ATG Dose 3 Date (recode: number of days after consent) |
| 26 | CR9FL1DT_DAYS | Num | 8 | | | Fludarabine Dose 1 Date (recode: number of days after consent) |
| 27 | CR9FL2DT_DAYS | Num | 8 | | | Fludarabine Dose 2 Date (recode: number of days after consent) |
| 28 | CR9FL3DT_DAYS | Num | 8 | | | Fludarabine Dose 3 Date (recode: number of days after consent) |
| 29 | CR9FL4DT_DAYS | Num | 8 | | | Fludarabine Dose 4 Date (recode: number of days after consent) |
| 30 | CR9FL5DT_DAYS | Num | 8 | | | Fludarabine Dose 5 Date (recode: number of days after consent) |
| 31 | CR9CY1DT_DAYS | Num | 8 | | | Cyclo Dose 1 Date (recode: number of days after consent) |
| 32 | CR9CY2DT_DAYS | Num | 8 | | | Cyclo Dose 2 Date (recode: number of days after consent) |
| 33 | CR9CY3DT_DAYS | Num | 8 | | | Cyclo Dose 3 Date (recode: number of days after consent) |
| 34 | CR9CY4DT_DAYS | Num | 8 | | | Cyclo Dose 4 Date (recode: number of days after consent) |
| 35 | CR9TBIDT_DAYS | Num | 8 | | | TBI Date (recode: number of days after consent) |

Data Set Name: dem.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|-----------|----------|---|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | GENDER | Char | 1 | \$X1399X. | \$1. | Gender |
| 4 | ETHNIC | Char | 3 | \$X2518X. | \$3. | Ethnicity |
| 5 | RACEG | Num | 8 | RACEGF. | | Race (grouped: 1=White, 2=Black, 3 = Asian/Pacific Islander, 9=Other/Unknown/Missing) |

Data Set Name: dth.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|------------|------|-----|-----------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | AUTPERF | Char | 1 | \$X1457X. | \$1. | Autopsy performed |
| 4 | CZDTHPRM | Char | 4 | \$X1488X. | \$4. | Primary Cause of Death |
| 5 | DTHSPEC1 | Char | 50 | \$50. | \$50. | Cause specify 1 |
| 6 | SCNDCZ1 | Char | 4 | \$X1488X. | \$4. | Secondary cause death |
| 7 | DTHSPEC2 | Char | 50 | \$50. | \$50. | Cause specify 2 |
| 8 | SCNDCZ2 | Char | 4 | \$X1488X. | \$4. | Secondary cause death |
| 9 | DTHSPEC3 | Char | 50 | \$50. | \$50. | Cause specify 3 |
| 10 | DTHDT_DAYS | Num | 8 | | | Date of Death (recode: number of days after consent) |

Data Set Name: *ecv.sas7bdat*

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|------------|----------|---|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | ECPRIRTX | Char | 1 | \$X1457X. | \$1. | Prior Rituxan |
| 6 | ECPRIALM | Char | 1 | \$X1457X. | \$1. | Prior Alemtuzumab |
| 7 | ECEBVSAM | Char | 1 | \$X1457X. | \$1. | EBV Sample |
| 8 | ECEBV TYP | Char | 1 | \$X30953X. | \$1. | EBV Test Type |
| 9 | ECEBVRES | Char | 1 | \$X1579X. | \$1. | EBV Test Result |
| 10 | ECEBVQNT | Char | 1 | \$X30729X. | \$1. | EBV Result Quantifiable |
| 11 | ECEBVVLD | Num | 8 | 10. | 10. | EBV Viral Load |
| 12 | ECEBVLIM | Num | 8 | 7. | 7. | EBV Detection Limit |
| 13 | ECCMVSAM | Char | 1 | \$X1457X. | \$1. | CMV Sample |
| 14 | ECCMV TYP | Char | 1 | \$X30953X. | \$1. | CMV Test Type |
| 15 | ECCMVRES | Char | 1 | \$X1579X. | \$1. | CMV Test Result |
| 16 | ECCMVQNT | Char | 1 | \$X30729X. | \$1. | CMV Result Quantifiable |
| 17 | ECCMVVLD | Num | 8 | 10. | 10. | CMV Viral Load |
| 18 | ECCMVLIM | Num | 8 | 7. | 7. | CMV Detection Limit |
| 19 | DTHDT_DAYS | Num | 8 | | | Date of Death (recode: number of days after consent) |
| 20 | TXD TTXP_DAYS | Num | 8 | | | Stem Cell Infusion Date (recode: number of days after consent) |
| 21 | ENRLDATE_DAYS | Num | 8 | | | ENRLDATE (recode: number of days after consent) |
| 22 | ECLRTXDT_DAYS | Num | 8 | | | Date of Last Rituxan (recode: number of days after consent) |
| 23 | ECLALMDT_DAYS | Num | 8 | | | Date of Last Alemtuzumab (recode: number of days after consent) |
| 24 | ECEBVODT_DAYS | Num | 8 | | | EBV Obtained Date (recode: number of days after consent) |
| 25 | ECCMVODT_DAYS | Num | 8 | | | CMV Obtained Date (recode: number of days after consent) |

Data Set Name: enr0.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|------------|----------|---|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | SADONTYP | Char | 1 | \$X42401X. | \$1. | Donor Type |
| 4 | SADONCON | Char | 1 | \$X1457X. | \$1. | Donor Consent |
| 5 | SADONRBM | Char | 1 | \$X1457X. | \$1. | Donor Able to Donate BM |
| 6 | SADONRWT | Char | 1 | \$X1457X. | \$1. | Donor Weight |
| 7 | ENRLDATE_DAYS | Num | 8 | | | Date of Enrollment (recode: number of days after consent) |
| 8 | STARTDT_DAYS | Num | 8 | | | Start Date (recode: number of days after consent) |

Data Set Name: enra.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|------------|----------|---------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | APA25CEL | Char | 1 | \$X1457X. | \$1. | Cellularity Less Than 25 |
| 4 | APA50CEL | Char | 1 | \$X1457X. | \$1. | Cellularity Less Than 50 |
| 5 | APANETR | Char | 1 | \$X1457X. | \$1. | Neutrophil Count |
| 6 | APAPLATE | Char | 1 | \$X1457X. | \$1. | Platelet Count |
| 7 | APARETIC | Char | 1 | \$X1457X. | \$1. | Reticulocyte Count |
| 8 | APAMATCH | Char | 1 | \$X1457X. | \$1. | Matched Donor |
| 9 | APAREFRA | Char | 1 | \$X1457X. | \$1. | Refractory after IST |
| 10 | APACARDI | Char | 1 | \$X42931X. | \$1. | Cardiac Function Measure |
| 11 | APALVEFV | Num | 8 | 4. | 4. | LVEF at Rest |
| 12 | APASFVAL | Num | 8 | 4. | 4. | Shortening Fraction |
| 13 | APAGILBE | Char | 1 | \$X1457X. | \$1. | Gilbert's Disease |
| 14 | APABILVA | Num | 8 | 6.1 | 6.1 | Bilirubin Value |
| 15 | APABIULN | Num | 8 | 6.1 | 6.1 | Bilirubin ULN |
| 16 | APAASTVA | Num | 8 | 4. | 4. | AST Value |
| 17 | APAASTUL | Num | 8 | 4. | 4. | AST ULN |
| 18 | APAALTVA | Num | 8 | 4. | 4. | ALT Value |
| 19 | APAALTUL | Num | 8 | 4. | 4. | ALT ULN |
| 20 | APACREAT | Num | 8 | 7.1 | 7.1 | Creatinine Clearance |
| 21 | APAGFRVA | Char | 1 | \$X1457X. | \$1. | Estimated GFR |
| 22 | APANUCGF | Char | 1 | \$X1457X. | \$1. | Nuclear GFR |
| 23 | APAPFTVA | Char | 1 | \$X1457X. | \$1. | Unable to Perform PFTs |
| 24 | APADLCOV | Num | 8 | 4. | 4. | DLCO Value |
| 25 | APAFEVIV | Num | 8 | 4. | 4. | FEV1 Value |
| 26 | APAFVCVA | Num | 8 | 4. | 4. | FVC Value |
| 27 | APADYSP | Char | 1 | \$X1457X. | \$1. | Dyspnea at Rest |
| 28 | APAOXYGE | Char | 1 | \$X1457X. | \$1. | Supplemental Oxygen |
| 29 | APAO2SAT | Num | 8 | 4. | 4. | O2 Saturation |
| 30 | APAPERFO | Char | 1 | \$X1652X. | \$1. | Performance Status Scale |
| 31 | APAPERST | Char | 2 | \$X2475X. | \$2. | Performance Status |
| 32 | APACHILD | Char | 1 | \$X1457X. | \$1. | Childbearing Potential |
| 33 | APACONTR | Char | 1 | \$X1457X. | \$1. | Agree to Contraception |
| 34 | APAANEM | Char | 1 | \$X1457X. | \$1. | Fanconi Anemia or Other |
| 35 | APACYTO | Char | 1 | \$X1457X. | \$1. | Cytogenetic Abnormalities |
| 36 | APAMYEDS | Char | 1 | \$X1457X. | \$1. | MDS |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|------------|----------|--|
| 37 | APAANTIB | Char | 1 | \$X1457X. | \$1. | HLA Antibodies |
| 38 | APAALLOG | Char | 1 | \$X1457X. | \$1. | Prior Allogeneic Txp |
| 39 | APAORGAN | Char | 1 | \$X1457X. | \$1. | Prior Organ Txp |
| 40 | APATHYMO | Char | 1 | \$X1457X. | \$1. | Thymoglobulin Reaction |
| 41 | APAINFEC | Char | 1 | \$X1457X. | \$1. | Uncontrolled Infection |
| 42 | APASEHIV | Char | 1 | \$X1457X. | \$1. | HIV Seropositive |
| 43 | APAHEPAT | Char | 1 | \$X1457X. | \$1. | Active Hepatitis |
| 44 | APAPREGN | Char | 1 | \$X1635X. | \$1. | Pregnant or Breastfeeding |
| 45 | APAMALIG | Char | 1 | \$X21301X. | \$1. | Prior Malignancies |
| 46 | APAALEMU | Char | 1 | \$X1457X. | \$1. | Alemtuzumab or ATG |
| 47 | APATELSM | Char | 1 | \$X1457X. | \$1. | Telomere Analysis Sample |
| 48 | APAFUTSM | Char | 1 | \$X1457X. | \$1. | Future Research Sample |
| 49 | APATLADN | Char | 1 | \$X1457X. | \$1. | Telomere Sample Donor |
| 50 | ENRLDATE_DAYS | Num | 8 | | | ENRLDATE (recode: number of days after consent) |
| 51 | STARTDT_DAYS | Num | 8 | | | Startdt (recode: number of days after consent) |
| 52 | APALVEDT_DAYS | Num | 8 | | | LVEF Date (recode: number of days after consent) |
| 53 | APASFRDT_DAYS | Num | 8 | | | Shortening Fraction Date (recode: number of days after consent) |
| 54 | APABILDT_DAYS | Num | 8 | | | Bilirubin Date (recode: number of days after consent) |
| 55 | APAASTDT_DAYS | Num | 8 | | | AST Date (recode: number of days after consent) |
| 56 | APAALTDT_DAYS | Num | 8 | | | ALT Date (recode: number of days after consent) |
| 57 | APACREDT_DAYS | Num | 8 | | | Creatinine Clearance Date (recode: number of days after consent) |
| 58 | APADLCDT_DAYS | Num | 8 | | | DLCO Date (recode: number of days after consent) |
| 59 | APAFEVDT_DAYS | Num | 8 | | | FEV1 Date (recode: number of days after consent) |
| 60 | APAFVCDT_DAYS | Num | 8 | | | FVC Date (recode: number of days after consent) |
| 61 | APATLSDT_DAYS | Num | 8 | | | Telomere Sample Date (recode: number of days after consent) |
| 62 | APAFSMDT_DAYS | Num | 8 | | | Future Sample Date (recode: number of days after consent) |
| 63 | APATLADT_DAYS | Num | 8 | | | Telomere Sample Donor Dt (recode: number of days after consent) |

Data Set Name: f22.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | Visit Number |
| 5 | F22PTDTH | Char | 1 | \$X1457X. | \$1. | Has Patient Died |
| 6 | F22INFEC | Char | 1 | \$X1457X. | \$1. | Any New Infections |
| 7 | F22PTLD | Char | 1 | \$X1457X. | \$1. | PTLD Diagnosis |
| 8 | F22HOSP | Char | 1 | \$X1457X. | \$1. | Patient Hospitalized |
| 9 | F22TRANS | Char | 1 | \$X1457X. | \$1. | Non-Protocol Transplant |
| 10 | F22SGF | Char | 1 | \$X1457X. | \$1. | Secondary Graft Failure |
| 11 | F22UAE | Char | 1 | \$X1457X. | \$1. | Any Unexpected AEs |
| 12 | F22CNTDT_DAYS | Num | 8 | | | Date of Last Contact (recode: number of days after consent) |
| 13 | F22DTHDT_DAYS | Num | 8 | | | Date of Patient Death (recode: number of days after consent) |
| 14 | F22INFDT_DAYS | Num | 8 | | | New Infection Date (recode: number of days after consent) |
| 15 | F22PTLDT_DAYS | Num | 8 | | | PTLD Diagnosis Date (recode: number of days after consent) |
| 16 | F22HSPDT_DAYS | Num | 8 | | | Hospitalization Date (recode: number of days after consent) |
| 17 | F22TRNDT_DAYS | Num | 8 | | | Non-Prot Transplant Date (recode: number of days after consent) |
| 18 | F22SGFDT_DAYS | Num | 8 | | | Secondary Graft Fail Date (recode: number of days after consent) |
| 19 | F22UAEDT_DAYS | Num | 8 | | | Unexpected AE Date (recode: number of days after consent) |

Data Set Name: fgy.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|------------|----------|---------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | FGGRAGVH | Char | 1 | \$X2235X. | \$1. | Max Grade of aGVHD |
| 6 | FGAGVDVL | Char | 1 | \$X1457X. | \$1. | aGVHD Develop This Assess |
| 7 | FGASKNAB | Char | 1 | \$X1825X. | \$1. | Acute Skin Abnormalities |
| 8 | FGAUGIAB | Char | 1 | \$X1830X. | \$1. | Acute Upper GI Abnormal |
| 9 | FGALGIAB | Char | 1 | \$X6636X. | \$1. | Acute Lower GI Abnormal |
| 10 | FGALVRAB | Char | 1 | \$X1829X. | \$1. | Acute Liver Abnormalities |
| 11 | FGPROPIM | Char | 1 | \$X11444X. | \$1. | Immuno for Prophylaxis |
| 12 | FGPRATG | Char | 1 | \$X1457X. | \$1. | ATG Prophylaxis |
| 13 | FGPRBORT | Char | 1 | \$X1457X. | \$1. | Bortizomib Prophylaxis |
| 14 | FGPRCAMP | Char | 1 | \$X1457X. | \$1. | Campath Prophylaxis |
| 15 | FGPRCYPH | Char | 1 | \$X1457X. | \$1. | Cyclophosphamide Prophyl |
| 16 | FGPRCYCL | Char | 1 | \$X1457X. | \$1. | Cyclosporine Prophylaxis |
| 17 | FGPRMMF | Char | 1 | \$X1457X. | \$1. | MMF Prophylaxis |
| 18 | FGPRMRVR | Char | 1 | \$X1457X. | \$1. | Maraviroc Prophylaxis |
| 19 | FGPRMTRX | Char | 1 | \$X1457X. | \$1. | Methotrexate Prophylaxis |
| 20 | FGPRPRED | Char | 1 | \$X1457X. | \$1. | Prednisone Prophylaxis |
| 21 | FGPRSIR | Char | 1 | \$X1457X. | \$1. | Sirolimus Prophylaxis |
| 22 | FGPRTAC | Char | 1 | \$X1457X. | \$1. | Tacrolimus Prophylaxis |
| 23 | FGPROTHR | Char | 1 | \$X1457X. | \$1. | Other Prophylaxis |
| 24 | FGPROTSP | Char | 50 | \$50. | \$50. | Specify Other Prophylaxis |
| 25 | FGSVCGVH | Char | 1 | \$X26575X. | \$1. | Max Severity of cGVHD |
| 26 | FGCGVDVL | Char | 1 | \$X1457X. | \$1. | cGVHD Develop This Assess |
| 27 | FGDGKNLN | Char | 2 | \$X12323X. | \$2. | Karnofsky/Lansky Diagnos |
| 28 | FGDGPLT | Num | 8 | 7. | 7. | Platelet Count Diagnosis |
| 29 | FGDGALKP | Num | 8 | 5. | 5. | Alkaline Phosph Diagnosis |
| 30 | FGDGWGT | Num | 8 | 7.1 | 7.1 | Weight at Diagnosis |
| 31 | FGDGBILI | Num | 8 | 6.1 | 6.1 | Total Bilirubin Diagnosis |
| 32 | FGRSDIAG | Char | 1 | \$X1457X. | \$1. | Rash at Diagnosis |
| 33 | FGDRDIAG | Char | 1 | \$X1457X. | \$1. | Diarrhea at Diagnosis |
| 34 | FGSKNINV | Char | 1 | \$X26585X. | \$1. | Extent Skin Involvement |
| 35 | FGRSLICH | Char | 1 | \$X1457X. | \$1. | Lichenoid Rash |
| 36 | FGRSMACU | Char | 1 | \$X1457X. | \$1. | Maculopapular Rash |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|------------|----------|---------------------------|
| 37 | FGRSSCLR | Char | 1 | \$X1457X. | \$1. | Sclerodermatous Rash |
| 38 | FGRSOTHR | Char | 1 | \$X1457X. | \$1. | Other Rash |
| 39 | FGRSOTSP | Char | 30 | \$30. | \$30. | Other Rash Specify |
| 40 | FGXEROPH | Char | 1 | \$X4540X. | \$1. | Xerophthalmia |
| 41 | FGMUCOS | Char | 1 | \$X4542X. | \$1. | Mucositis (functional) |
| 42 | FGBRNCH | Char | 1 | \$X5284X. | \$1. | Bronchiolitis Obliterans |
| 43 | FGFEV1VL | Num | 8 | 4. | 4. | FEV1 Value |
| 44 | FGFVCVL | Num | 8 | 4. | 4. | FVC Value |
| 45 | FGDLCOVL | Num | 8 | 4. | 4. | DLCO Value |
| 46 | FGESOPH | Char | 1 | \$X26577X. | \$1. | Esophagus |
| 47 | FGNAUSVM | Char | 1 | \$X1830X. | \$1. | Nausea and Vomiting |
| 48 | FGDIARH | Char | 1 | \$X5654X. | \$1. | Diarrhea |
| 49 | FGBILI | Num | 8 | 6.1 | 6.1 | Bilirubin Value |
| 50 | FGALT | Num | 8 | 5. | 5. | ALT Value |
| 51 | FGAST | Num | 8 | 5. | 5. | AST Value |
| 52 | FGALKPH | Num | 8 | 5. | 5. | Alkaline Phosph Value |
| 53 | FGVAGNIT | Char | 1 | \$X4553X. | \$1. | Non-infective Vaginitis |
| 54 | FGCONTRC | Char | 1 | \$X26578X. | \$1. | Contractures |
| 55 | FGMYOSIT | Char | 1 | \$X1457X. | \$1. | Myositis |
| 56 | FGEOSINP | Char | 1 | \$X1457X. | \$1. | Eosinophilia |
| 57 | FGSEROS | Char | 1 | \$X1457X. | \$1. | Serositis |
| 58 | FGFASCIT | Char | 1 | \$X1457X. | \$1. | Fascitis |
| 59 | FGOTORGN | Char | 1 | \$X1457X. | \$1. | Other Organ Involve |
| 60 | FGBIOPSY | Char | 1 | \$X1457X. | \$1. | Biopsy for GVHD |
| 61 | FGBIO1TY | Char | 1 | \$X5285X. | \$1. | Biopsy Type 1 |
| 62 | FGBIO1RS | Char | 1 | \$X26579X. | \$1. | Biopsy Result 1 |
| 63 | FGBIO2TY | Char | 1 | \$X5285X. | \$1. | Biopsy Type 2 |
| 64 | FGBIO2RS | Char | 1 | \$X26579X. | \$1. | Biopsy Result 2 |
| 65 | FGCHRTRT | Char | 1 | \$X26581X. | \$1. | Treatment of Chronic GVHD |
| 66 | FGTHATG | Char | 1 | \$X1457X. | \$1. | ALS, ALG, ATS, ATG Therap |
| 67 | FGTHAZAT | Char | 1 | \$X1457X. | \$1. | Azathioprine Therapy |
| 68 | FGTHCYCL | Char | 1 | \$X1457X. | \$1. | Cyclosporine Therapy |
| 69 | FGTHSYCO | Char | 1 | \$X1457X. | \$1. | Systemic Cortico Therapy |
| 70 | FGTHTPCO | Char | 1 | \$X1457X. | \$1. | Topical Cortico Therapy |
| 71 | FGTHTHAL | Char | 1 | \$X1457X. | \$1. | Thalidomide Therapy |
| 72 | FGTHTAC | Char | 1 | \$X1457X. | \$1. | Tacrolimus-FK506 Therapy |
| 73 | FGTHMMF | Char | 1 | \$X1457X. | \$1. | MMF Therapy |
| 74 | FGTHPUVA | Char | 1 | \$X1457X. | \$1. | PUVA Therapy |
| 75 | FGTHECP | Char | 1 | \$X1457X. | \$1. | ECP Therapy |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|--|
| 76 | FGTHSIR | Char | 1 | \$X1457X. | \$1. | Sirolimus Therapy |
| 77 | FGTHETR | Char | 1 | \$X1457X. | \$1. | Etretinate Therapy |
| 78 | FGTHLAMP | Char | 1 | \$X1457X. | \$1. | Lamprene Therapy |
| 79 | FGTHETAN | Char | 1 | \$X1457X. | \$1. | Etanercept Therapy |
| 80 | FGTHZENA | Char | 1 | \$X1457X. | \$1. | Zenapax Therapy |
| 81 | FGTHCHPH | Char | 1 | \$X1457X. | \$1. | Chloroquine Phosph Therap |
| 82 | FGTHMAB | Char | 1 | \$X1457X. | \$1. | In Vivo MAB Therapy |
| 83 | FGTHIMM | Char | 1 | \$X1457X. | \$1. | In Vivio Immuno Therapy |
| 84 | FGTHOTHR | Char | 1 | \$X1457X. | \$1. | Other Therapy |
| 85 | FGTHOTSP | Char | 50 | \$50. | \$50. | Specify Other Agent |
| 86 | DTPRVAST_DAYS | Num | 8 | | | Start Date of Assessment (recode: number of days after consent) |
| 87 | DTASSESS_DAYS | Num | 8 | | | End Date of Assessment (recode: number of days after consent) |
| 88 | FGAGDGDТ_DAYS | Num | 8 | | | Date aGVHD Diagnosed (recode: number of days after consent) |
| 89 | FGPRDCDT_DAYS | Num | 8 | | | GVHD Prophyl Discont Date (recode: number of days after consent) |
| 90 | FGCGDGDТ_DAYS | Num | 8 | | | Date cGVHD Diagnosed (recode: number of days after consent) |
| 91 | FGFEV1DT_DAYS | Num | 8 | | | Date FEV1 obtained (recode: number of days after consent) |
| 92 | FGBILIDТ_DAYS | Num | 8 | | | Date Bilirubin Obtained (recode: number of days after consent) |
| 93 | FGALTDТ_DAYS | Num | 8 | | | Date ALT Obtained (recode: number of days after consent) |
| 94 | FGASTDТ_DAYS | Num | 8 | | | Date AST Obtained (recode: number of days after consent) |
| 95 | FGAKPHDТ_DAYS | Num | 8 | | | Date Alkaline Phos Obtain (recode: number of days after consent) |
| 96 | FGBIO1DТ_DAYS | Num | 8 | | | Biopsy Date 1 (recode: number of days after consent) |
| 97 | FGBIO2DТ_DAYS | Num | 8 | | | Biopsy Date 2 (recode: number of days after consent) |
| 98 | FGCTRTDТ_DAYS | Num | 8 | | | Date Chronic Treat Start (recode: number of days after consent) |

Data Set Name: gvh.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|-----------|------|-----|------------|----------|---------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | IMMUNORC | Char | 1 | \$X54237X. | \$1. | Immunosuppressant Recvd |
| 6 | TROUGHLEV | Num | 8 | 8.1 | 8.1 | Most Recent Immun Level |
| 7 | GVHSKINA | Char | 1 | \$X1825X. | \$1. | Skin Abnormalities |
| 8 | SETGVHD | Char | 1 | \$X1457X. | \$1. | Skin Etiology GVHD |
| 9 | SETDRGRX | Char | 1 | \$X1457X. | \$1. | Skin Etiology Drug Reacti |
| 10 | SETCRTOX | Char | 1 | \$X1457X. | \$1. | Skin Etiology Cnd Reg Tox |
| 11 | SETINFCT | Char | 1 | \$X1457X. | \$1. | Skin Etiology Infection |
| 12 | SETOTHER | Char | 1 | \$X1457X. | \$1. | Skin Etiology Other |
| 13 | GVHSKNSP | Char | 50 | \$50. | \$50. | Skin Etiology Specify |
| 14 | GVHSKINB | Char | 1 | \$X1822X. | \$1. | Skin Biopsy Results |
| 15 | GVHUPGIA | Char | 1 | \$X1830X. | \$1. | Upper GI Abnormalities |
| 16 | UGIETGVH | Char | 1 | \$X1457X. | \$1. | UGI Etiology GVHD |
| 17 | UGIETDRG | Char | 1 | \$X1457X. | \$1. | UGI Etiology Drug Rxn |
| 18 | UGIETCON | Char | 1 | \$X1457X. | \$1. | UGI Etiology Cond Reg Tox |
| 19 | UGIETTPN | Char | 1 | \$X1457X. | \$1. | UGI Etiology TPN |
| 20 | UGIETINF | Char | 1 | \$X1457X. | \$1. | UGI Etiology Infection |
| 21 | UGIETOTH | Char | 1 | \$X1457X. | \$1. | UGI Etiology Other |
| 22 | UGIETSPC | Char | 50 | \$50. | \$50. | UGI Etiology Specify |
| 23 | UGIBIORS | Char | 1 | \$X1822X. | \$1. | UGI Biopsy Results |
| 24 | GVHINTA | Char | 1 | \$X6636X. | \$1. | Lower GI Abnormalities |
| 25 | LGIETGVH | Char | 1 | \$X1457X. | \$1. | LGI Etiology GVHD |
| 26 | LGIETDRG | Char | 1 | \$X1457X. | \$1. | LGI Etiology Drug Rxn |
| 27 | LGIETCON | Char | 1 | \$X1457X. | \$1. | LGI Etiology Cond Reg Tox |
| 28 | LGIETTPN | Char | 1 | \$X1457X. | \$1. | LGI Etiology TPN |
| 29 | LGIETINF | Char | 1 | \$X1457X. | \$1. | LGI Etiology Infection |
| 30 | LGIETOTH | Char | 1 | \$X1457X. | \$1. | LGI Etiology Other |
| 31 | LGIETSPC | Char | 50 | \$50. | \$50. | LGI Etiology Specify |
| 32 | LGIBIORS | Char | 1 | \$X1822X. | \$1. | LGI Biopsy Results |
| 33 | GVHLIVRA | Char | 1 | \$X1829X. | \$1. | Liver Abnormalities |
| 34 | LIVETGVH | Char | 1 | \$X1457X. | \$1. | Liver Etiology GVHD |
| 35 | LIVETDRG | Char | 1 | \$X1457X. | \$1. | Liver Etiology Drug Rxn |
| 36 | LIVETCND | Char | 1 | \$X1457X. | \$1. | Liver Etiology Cnd Reg Tx |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|---|
| 37 | LIVETTPN | Char | 1 | \$X1457X. | \$1. | Liver Etiology TPN |
| 38 | LIVETINF | Char | 1 | \$X1457X. | \$1. | Liver Etiology Infection |
| 39 | LIVETVOD | Char | 1 | \$X1457X. | \$1. | Liver Etiology VOD |
| 40 | LIVETOTH | Char | 1 | \$X1457X. | \$1. | Liver Etiology Other |
| 41 | GVHLIVRS | Char | 50 | \$50. | \$50. | Liver Etiology Specify |
| 42 | GVHLIVRB | Char | 1 | \$X1822X. | \$1. | Liver Biopsy Results |
| 43 | GVHTHERP | Char | 1 | \$X1457X. | \$1. | GVHD Treatment Modified? |
| 44 | GVHAGENT | Char | 1 | \$X2166X. | \$1. | Agent Type |
| 45 | GVHAGNSP | Char | 50 | \$50. | \$50. | Specify Agent |
| 46 | GVHTRMOD | Char | 1 | \$X2165X. | \$1. | Modification of Treatment |
| 47 | STAGEDT_DAYS | Num | 8 | | | Date of GvHD Staging (recode: number of days after consent) |
| 48 | GVASSTDT_DAYS | Num | 8 | | | Start of GVHD Ass Period (recode: number of days after consent) |
| 49 | GVASENDT_DAYS | Num | 8 | | | End of GVHD Ass Period (recode: number of days after consent) |
| 50 | TROUGHDT_DAYS | Num | 8 | | | Dt of Most Recent Immun (recode: number of days after consent) |

Data Set Name: h04.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|------------|----------|---------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | HXXRAMET | Char | 1 | \$X11437X. | \$1. | Recipient HLA-A Method |
| 6 | HXXA1REC | Char | 100 | \$100. | \$100. | Recipient HLA-A 1 |
| 7 | HXXA2REC | Char | 100 | \$100. | \$100. | Recipient HLA-A 2 |
| 8 | HXXRBMET | Char | 1 | \$X11437X. | \$1. | Recipient HLA-B Method |
| 9 | HXXB1REC | Char | 100 | \$100. | \$100. | Recipient HLA-B 1 |
| 10 | HXXB2REC | Char | 100 | \$100. | \$100. | Recipient HLA-B 2 |
| 11 | HXXRCMET | Char | 1 | \$X11437X. | \$1. | Recipient HLA-C Method |
| 12 | HXXC1REC | Char | 100 | \$100. | \$100. | Recipient HLA-C 1 |
| 13 | HXXC2REC | Char | 100 | \$100. | \$100. | Recipient HLA-C 2 |
| 14 | HXXRDMET | Char | 1 | \$X11437X. | \$1. | Recipient HLA-DRB1 Method |
| 15 | HXXD1REC | Char | 100 | \$100. | \$100. | Recipient HLA-DRB1 1 |
| 16 | HXXD2REC | Char | 100 | \$100. | \$100. | Recipient HLA-DRB1 2 |
| 17 | HXXRQMET | Char | 1 | \$X11437X. | \$1. | Recipient HLA-DQ Method |
| 18 | HXXQ1REC | Char | 100 | \$100. | \$100. | Recipient HLA-DQB1 1 |
| 19 | HXXQ2REC | Char | 100 | \$100. | \$100. | Recipient HLA-DQB1 2 |
| 20 | HXXDNTYP | Char | 1 | \$X42401X. | \$1. | Donor Type |
| 21 | HXXDAMET | Char | 1 | \$X11437X. | \$1. | Donor HLA-A Method |
| 22 | HXXA1DON | Char | 100 | \$100. | \$100. | Donor HLA-A 1 |
| 23 | HXXA2DON | Char | 100 | \$100. | \$100. | Donor HLA-A 2 |
| 24 | HXXDBMET | Char | 1 | \$X11437X. | \$1. | Donor HLA-B Method |
| 25 | HXXB1DON | Char | 100 | \$100. | \$100. | Donor HLA-B 1 |
| 26 | HXXB2DON | Char | 100 | \$100. | \$100. | Donor HLA-B2 |
| 27 | HXXDCMET | Char | 1 | \$X11437X. | \$1. | Donor HLA-C Method |
| 28 | HXXC1DON | Char | 100 | \$100. | \$100. | Donor HLA-C 1 |
| 29 | HXXC2DON | Char | 100 | \$100. | \$100. | Donor HLA-C 2 |
| 30 | HXXDDMET | Char | 1 | \$X11437X. | \$1. | Donor HLA-DRB1 Method |
| 31 | HXXD1DON | Char | 100 | \$100. | \$100. | Donor HLA-DRB1 1 |
| 32 | HXXD2DON | Char | 100 | \$100. | \$100. | Donor HLA-DRB1 2 |
| 33 | HXXDQMET | Char | 1 | \$X11437X. | \$1. | Donor HLA-DQ Method |
| 34 | HXXQ1DON | Char | 100 | \$100. | \$100. | Donor HLA-DQB1 1 |
| 35 | HXXQ2DON | Char | 100 | \$100. | \$100. | Donor HLA-DQB1 2 |
| 36 | HXXHRQD | Char | 5 | \$5. | \$5. | Score Required by Prot |

| Num | Variable | Type | Len | Format | Informat | Label |
|------------|-----------------|-------------|------------|---------------|-----------------|---------------------------|
| 37 | HXXSCRA | Char | 3 | \$3. | \$3. | Locus A Calculated Score |
| 38 | HXXSCRB | Char | 3 | \$3. | \$3. | Locus B Calculated Score |
| 39 | HXXSCRC | Char | 3 | \$3. | \$3. | Locus C Calculated Score |
| 40 | HXXSCRD | Char | 3 | \$3. | \$3. | Locus D Calculated Score |
| 41 | HXXSCRQ | Char | 3 | \$3. | \$3. | Locus Q Calculated Score |
| 42 | HXXHLA | Char | 5 | \$5. | \$5. | Total Calculated Score |
| 43 | HXXSISC | Char | 5 | \$X54104X. | \$5. | Institution's Match Score |

Data Set Name: hf7.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|---|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | ANCDRP | Char | 1 | \$X1457X. | \$1. | Patient's ANC Drop |
| 6 | ANCREC | Char | 1 | \$X1645X. | \$1. | ANC Recovery 500 |
| 7 | D1ANC | Num | 8 | 6. | 6. | Day 1 ANC |
| 8 | D2ANC | Num | 8 | 6. | 6. | Day 2 ANC |
| 9 | D3ANC | Num | 8 | 6. | 6. | Day 3 ANC |
| 10 | RECNTANC | Num | 8 | 6. | 6. | Most Recent ANC Count |
| 11 | MRWCHIM | Char | 1 | \$X1457X. | \$1. | Chimerism Assay Marrow |
| 12 | MRWMTHD | Char | 1 | \$X1500X. | \$1. | Marrow Method Collection |
| 13 | UNFTYP | Char | 1 | \$X4470X. | \$1. | Unfractionated type |
| 14 | MRWRSLT | Char | 1 | \$X1522X. | \$1. | Marrow Assay Results |
| 15 | MRWPCTD | Num | 8 | 3. | 3. | Marrow Percent Donor |
| 16 | TCLCHIM | Char | 1 | \$X1457X. | \$1. | Chimerism Assay T Cell |
| 17 | TCLMTHD | Char | 1 | \$X1500X. | \$1. | T Cell Method Collection |
| 18 | TCLTYPE | Char | 1 | \$X4470X. | \$1. | T Cell Sample Type |
| 19 | TCLRSLT | Char | 1 | \$X1522X. | \$1. | T Cell Assay Results |
| 20 | TCLPCTD | Num | 8 | 3. | 3. | T Cell Percent Donor |
| 21 | D1ANCDT_DAYS | Num | 8 | | | Day 1 ANC Date (recode: number of days after consent) |
| 22 | D2ANCDT_DAYS | Num | 8 | | | Day 2 ANC Date (recode: number of days after consent) |
| 23 | D3ANCDT_DAYS | Num | 8 | | | Day 3 ANC Date (recode: number of days after consent) |
| 24 | RCTANCDT_DAYS | Num | 8 | | | Most Recent ANC Date (recode: number of days after consent) |
| 25 | MRWCHIDT_DAYS | Num | 8 | | | Marrow Collection Date (recode: number of days after consent) |
| 26 | TCLCHIDT_DAYS | Num | 8 | | | T Cell Collection Date (recode: number of days after consent) |

Data Set Name: ifn.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|------------|-----------------|-------------|------------|---------------|-----------------|---------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | INFSITE | Char | 2 | \$XINFSITEX. | \$2. | Infection Site |
| 5 | IFN1NMCR | Char | 1 | \$X1457X. | \$1. | Infect 1 Nonmicrobiologic |
| 6 | IFN1PTPN | Char | 1 | \$X1457X. | \$1. | Infect 1 Pt Pneumonia |
| 7 | IFN1PTVT | Char | 1 | \$X1457X. | \$1. | Infect 1 Pt Ventilation |
| 8 | IFN1PTTY | Char | 1 | \$X1457X. | \$1. | Infect 1 Pt Typhlitis |
| 9 | IFN1PSEP | Char | 1 | \$X1457X. | \$1. | Infect 1 Pt Severe Sepsis |
| 10 | IFN1TYPE | Char | 1 | \$X1507X. | \$1. | Infection 1 Type |
| 11 | IFN1ORGN | Char | 3 | \$X1371X. | \$3. | Infection 1 Organism |
| 12 | IFN1OTSP | Char | 50 | \$50. | \$50. | Infection 1 Other Specify |
| 13 | IFN1SVRT | Char | 1 | \$X28311X. | \$1. | Infection 1 Severity |
| 14 | IFN1EVSP | Char | 1 | \$X1457X. | \$1. | Infect 1 Evidence Sepsis |
| 15 | IFN1EVIN | Char | 1 | \$X1457X. | \$1. | Infect 1 Evid Infiltrates |
| 16 | IFN2NMCR | Char | 1 | \$X1457X. | \$1. | Infect 2 Nonmicrobiologic |
| 17 | IFN2TYPE | Char | 1 | \$X1507X. | \$1. | Infection 2 Type |
| 18 | IFN2ORGN | Char | 3 | \$X1371X. | \$3. | Infection 2 Organism |
| 19 | IFN2SVRT | Char | 1 | \$X28311X. | \$1. | Infection 2 Severity |
| 20 | IFN2EVSP | Char | 1 | \$X1457X. | \$1. | Infect 2 Evidence Sepsis |
| 21 | IFN2EVIN | Char | 1 | \$X1457X. | \$1. | Infect 2 Evid Infiltrates |
| 22 | IFN3NMCR | Char | 1 | \$X1457X. | \$1. | Infect 3 Nonmicrobiologic |
| 23 | IFN3TYPE | Char | 1 | \$X1507X. | \$1. | Infection 3 Type |
| 24 | IFN3ORGN | Char | 3 | \$X1371X. | \$3. | Infection 3 Organism |
| 25 | IFN3SVRT | Char | 1 | \$X28311X. | \$1. | Infection 3 Severity |
| 26 | IFN3EVSP | Char | 1 | \$X1457X. | \$1. | Infect 3 Evidence Sepsis |
| 27 | IFN3EVIN | Char | 1 | \$X1457X. | \$1. | Infect 3 Evid Infiltrates |
| 28 | IFNAGTRT | Char | 1 | \$X1457X. | \$1. | Agent Given to Treat Inf |
| 29 | IFN1AGNT | Char | 50 | \$X2850X. | \$50. | 1st Agent Given |
| 30 | IFN1AGSP | Char | 50 | \$50. | \$50. | 1st Agent Other Specify |
| 31 | IFN2AGNT | Char | 50 | \$X2850X. | \$50. | 2nd Agent Given |
| 32 | IFN2AGSP | Char | 50 | \$50. | \$50. | 2nd Agent Other Specify |
| 33 | IFN3AGNT | Char | 50 | \$X2850X. | \$50. | 3rd Agent Given |
| 34 | IFN3AGSP | Char | 50 | \$50. | \$50. | 3rd Agent Other Specify |
| 35 | IFNADDAG | Char | 1 | \$X1457X. | \$1. | Additional Agent Given |
| 36 | IFNADDSP | Char | 50 | \$50. | \$50. | Additional Agent Specify |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|--------------|------|-----|--------|----------|---|
| 37 | INFSTDT_DAYS | Num | 8 | | | Infection Start Date (recode: number of days after consent) |

Data Set Name: ir2.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | CD3AB | Num | 8 | 5. | 5. | CD3 Absolute |
| 6 | CD4AB | Num | 8 | 5. | 5. | CD4 Absolute |
| 7 | CD8AB | Num | 8 | 5. | 5. | CD8 Absolute |
| 8 | CD19AB | Num | 8 | 5. | 5. | CD19 Absolute |
| 9 | CD1656AB | Num | 8 | 5. | 5. | CD56 Absolute Count |
| 10 | QIGA | Num | 8 | 4. | 4. | Quantitative IgA |
| 11 | QIGG | Num | 8 | 5. | 5. | Quantitative IgG |
| 12 | QIGM | Num | 8 | 4. | 4. | Quantitative IgM |
| 13 | IVIGADMN | Char | 1 | \$X1457X. | \$1. | Immunoglobulin Admin |
| 14 | FLOWCYDT_DAYS | Num | 8 | | | Date Flow Cytometry (recode: number of days after consent) |
| 15 | QIMGSDT_DAYS | Num | 8 | | | Ig Sample Collection Date (recode: number of days after consent) |
| 16 | IVIGLSDT_DAYS | Num | 8 | | | Immunoglobulin Admin Date (recode: number of days after consent) |

Data Set Name: l11.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | L11RBCVL | Num | 8 | 5.1 | 5.1 | Red Blood Cell Value |
| 6 | L11HCTVL | Num | 8 | 6.1 | 6.1 | Hematocrit Value |
| 7 | L11HGBVL | Num | 8 | 6.1 | 6.1 | Hemoglobin Value |
| 8 | L11WBCVL | Num | 8 | 7. | 7. | White Blood Cell Value |
| 9 | L11PLTVL | Num | 8 | 7. | 7. | Platelet Count Value |
| 10 | L11NEUVL | Num | 8 | 7.1 | 7.1 | Neutrophils Value |
| 11 | L11LYMVL | Num | 8 | 7.1 | 7.1 | Lymphocytes Value |
| 12 | L11MONVL | Num | 8 | 7.1 | 7.1 | Monocytes Value |
| 13 | L11GRNVL | Num | 8 | 7.1 | 7.1 | Granulocytes Value |
| 14 | L11EOSVL | Num | 8 | 7.1 | 7.1 | Eosinophils Value |
| 15 | L11BASVL | Num | 8 | 7.1 | 7.1 | Basophils Value |
| 16 | L11TRIND | Char | 1 | \$X1457X. | \$1. | Transfusion Independent |
| 17 | L11RETIC | Num | 8 | 4. | 4. | Reticulocyte Count |
| 18 | L11AS1DT_DAYS | Num | 8 | | | Assessment Date 1 (recode: number of days after consent) |
| 19 | L11AS2DT_DAYS | Num | 8 | | | Assessment Date 2 (recode: number of days after consent) |
| 20 | L11RB1DT_DAYS | Num | 8 | | | Red Blood Cell Date 1 (recode: number of days after consent) |
| 21 | L11RB2DT_DAYS | Num | 8 | | | Red Blood Cell Date 2 (recode: number of days after consent) |
| 22 | L11HC1DT_DAYS | Num | 8 | | | Hematocrit Date 1 (recode: number of days after consent) |
| 23 | L11HC2DT_DAYS | Num | 8 | | | Hematocrit Date 2 (recode: number of days after consent) |
| 24 | L11HG1DT_DAYS | Num | 8 | | | Hemoglobin Date 1 (recode: number of days after consent) |
| 25 | L11HG2DT_DAYS | Num | 8 | | | Hemoglobin Date 2 (recode: number of days after consent) |
| 26 | L11WB1DT_DAYS | Num | 8 | | | White Blood Cell Date 1 (recode: number of days after consent) |
| 27 | L11WB2DT_DAYS | Num | 8 | | | White Blood Cell Date 2 (recode: number of days after consent) |
| 28 | L11PL1DT_DAYS | Num | 8 | | | Platelet Count Date 1 (recode: number of days after consent) |
| 29 | L11PL2DT_DAYS | Num | 8 | | | Platelet Count Date 2 (recode: number of days after consent) |
| 30 | L11NE1DT_DAYS | Num | 8 | | | Neutrophils Date 1 (recode: number of days after consent) |
| 31 | L11NE2DT_DAYS | Num | 8 | | | Neutrophil Date 2 (recode: number of days after consent) |
| 32 | L11LY1DT_DAYS | Num | 8 | | | Lymphocytes Date 1 (recode: number of days after consent) |
| 33 | L11LY2DT_DAYS | Num | 8 | | | Lymphocytes Date 2 (recode: number of days after consent) |
| 34 | L11MO1DT_DAYS | Num | 8 | | | Monocytes Date 1 (recode: number of days after consent) |
| 35 | L11MO2DT_DAYS | Num | 8 | | | Monocytes Date 2 (recode: number of days after consent) |
| 36 | L11GR1DT_DAYS | Num | 8 | | | Granulocytes Date 1 (recode: number of days after consent) |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|--------|----------|--|
| 37 | L11GR2DT_DAYS | Num | 8 | | | Granulocytes Date 2 (recode: number of days after consent) |
| 38 | L11EO1DT_DAYS | Num | 8 | | | Eosinophils Date 1 (recode: number of days after consent) |
| 39 | L11EO2DT_DAYS | Num | 8 | | | Eosinophils Date 2 (recode: number of days after consent) |
| 40 | L11BA1DT_DAYS | Num | 8 | | | Basophils Date 1 (recode: number of days after consent) |
| 41 | L11BA2DT_DAYS | Num | 8 | | | Basophils Date 2 (recode: number of days after consent) |
| 42 | L11RETDT_DAYS | Num | 8 | | | Reticulocyte Count Date (recode: number of days after consent) |

Data Set Name: outcomes.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|-------------------|------|-----|------------|----------|---|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | RACEETHG | Char | 50 | | | Recipient Race/Ethnicity (regrouped) |
| 3 | DIAG2TXP | Num | 8 | | | Months from Diagnosis to Transplant |
| 4 | DIAG2TXP_INT | Char | 10 | | | Diagnosis to Transplant Interval |
| 5 | SADONTYP | Char | 1 | \$X42401X. | \$1. | Patient's Donor Type |
| 6 | CZDTHPRM | Char | 4 | \$X1488X. | \$4. | Primary Cause of Death |
| 7 | DTHSPEC1 | Char | 50 | \$50. | \$50. | Specify 'Other' Cause of Death |
| 8 | ALIVE_ENGRAFT_1YR | Char | 3 | \$3. | \$3. | ERC-adjudicated Alive and Engrafted at 1 Year Post-TXP |
| 9 | PGF_D56 | Char | 3 | \$3. | \$3. | ERC-adjudicated Primary Graft Failure by Day 56 Post-TXP |
| 10 | SGF | Char | 3 | \$3. | \$3. | ERC-adjudicated Secondary Graft Failure |
| 11 | AUTOLOG | Char | 3 | \$3. | \$3. | ERC-adjudicated Alive with Autologous Recovery at 1 Year Post-TXP |
| 12 | MAXGRADE | Num | 8 | | | Maximum aGVHD Grade |
| 13 | FGSVCVH | Char | 1 | \$X26575X. | \$1. | Maximum Severity of cGVHD |
| 14 | F22PTLD | Char | 1 | \$X1457X. | \$1. | Post-Transplant Lymphoproliferative Disease (PTLD) |
| 15 | AGE | Num | 8 | | | Recipient Age |
| 16 | AGE_INT | Char | 10 | | | Recipient Age interval |
| 17 | DAGE | Num | 8 | | | Donor Age |
| 18 | ETHNIC | Char | 3 | \$X2518X. | \$3. | Recipient Ethnicity |
| 19 | DONOR_ETHNICITY | Char | 70 | | | Donor Ethnicity |
| 20 | GENDER2 | Char | 1 | \$GENDERF. | | Recipient Gender |
| 21 | DONOR_GENDER | Char | 70 | | | Donor Gender |
| 22 | RECIPIENT_BLOOD | Char | 24 | | | Recipient Blood Type |
| 23 | DONOR_BLOOD | Char | 24 | | | Donor Blood Type |
| 24 | HXXHLA | Char | 5 | \$5. | \$5. | HLA Match Score |
| 25 | CR9PTIBW | Num | 8 | 7.1 | 7.1 | Ideal Body Weight (IBW) |
| 26 | TNCCTINF | Num | 8 | 8.2 | 8.2 | TNC Count (10 ⁸ cells) |
| 27 | TNC_IBW | Num | 8 | | | TNC per recipient IBW (10 ⁸ cells/kg) |
| 28 | CDCNTINF | Num | 8 | 9.2 | 9.2 | CD34 Count (10 ⁶ cells) |
| 29 | CD34_IBW | Num | 8 | | | CD34 per recipient IBW (10 ⁶ cells/kg) |
| 30 | CD3AB | Num | 8 | 5. | 5. | CD3 Count (cells/uL) |
| 31 | CD3_IBW | Num | 8 | | | CD3 per recipient IBW (cells/uL per kg) |
| 32 | L11RBCVL | Num | 8 | 5.1 | 5.1 | RBC count (million/uL) |
| 33 | APABILVA | Num | 8 | 6.1 | 6.1 | Serum Bilirubin Level, mg/dL |
| 34 | APACREAT | Num | 8 | 7.1 | 7.1 | Serum Creatinine Level |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|---|
| 35 | APAPERST | Char | 2 | \$X2475X. | \$2. | Lansky/Karnofsky Performance Score |
| 36 | ANCDAY | Num | 8 | | | Neutrophil Recovery Days since transplant |
| 37 | ANCOUTCOME | Char | 9 | | | Neutrophil Recovery |
| 38 | ANCCENS | Num | 8 | INDF. | | Neutrophil Recovery Indicator |
| 39 | ANC_CI | Num | 8 | INDF. | | Neutrophil Recovery Competing Risk |
| 40 | OSTDAY | Num | 8 | | | Overall Survival Days since Transplant |
| 41 | OSTMON | Num | 8 | | | Overall Survival Months since Transplant |
| 42 | OSTVENT | Char | 9 | | | Overall Survival Outcome |
| 43 | OSTSRVCENS | Num | 8 | INDF. | | Overall Survival Indicator |
| 44 | AGVH234DAY | Num | 8 | | | Grades II-IV aGVHD Days since Transplant |
| 45 | GVH234OUTCOME | Char | 9 | | | Grades II-IV aGVHD Outcome |
| 46 | GVH234CENS | Num | 8 | INDF. | | Grades II-IV aGVHD Indicator |
| 47 | GVH234_CI | Num | 8 | INDF. | | Grades II-IV aGVHD Competing Risk |
| 48 | AGVH34DAY | Num | 8 | | | Grades III-IV aGVHD Days since Transplant |
| 49 | GVH34OUTCOME | Char | 9 | | | Grades III-IV aGVHD Outcome |
| 50 | GVH34CENS | Num | 8 | INDF. | | Grades III-IV aGVHD Indicator |
| 51 | GVH34_CI | Num | 8 | INDF. | | Grades III-IV aGVHD Competing Risk |
| 52 | CGVHDDAY | Num | 8 | | | cGVHD Days since Transplant |
| 53 | CGVHDMON | Num | 8 | | | cGVHD Months since Transplant |
| 54 | CGVHDOUTCOME | Char | 9 | | | cGVHD Outcome |
| 55 | CGVHDCENS | Num | 8 | INDF. | | cGVHD Indicator |
| 56 | CGVHD_CI | Num | 8 | INDF. | | cGVHD Competing Risk |
| 57 | EBVDAY | Num | 8 | | | EBV Days since Transplant |
| 58 | EBVMON | Num | 8 | | | EBV Months since Transplant |
| 59 | EBVOUTCOME | Char | 9 | | | EBV Outcome |
| 60 | EBVCENS | Num | 8 | INDF. | | EBV Indicator |
| 61 | EBV_CI | Num | 8 | INDF. | | EBV Competing Risk |
| 62 | DRCMVPR | Num | 8 | DRCMVPRF. | | Donor/Recipient CMV Serostatus |
| 63 | CMVDAY | Num | 8 | | | CMV Days since Transplant |
| 64 | CMVMON | Num | 8 | | | CMV Months since Transplant |
| 65 | CMVOUTCOME | Char | 9 | | | CMV Outcome |
| 66 | CMVCENS | Num | 8 | INDF. | | CMV Indicator |
| 67 | CMV_CI | Num | 8 | INDF. | | CMV Competing Risk |
| 68 | PTLDDAY | Num | 8 | | | PTLD Days since Transplant |
| 69 | PTLDMON | Num | 8 | | | PTLD Months since Transplant |
| 70 | PTLDOUTCOME | Char | 9 | | | PTLD Outcome |
| 71 | PTLDCENS | Num | 8 | INDF. | | PTLD Indicator |
| 72 | PTLD_CI | Num | 8 | INDF. | | PTLD Competing Risk |
| 73 | GFSTDAY | Num | 8 | | | Graft Failure-Free Survival Days since Transplant |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|------------------------|------|-----|--------|----------|--|
| 74 | GFSTMON | Num | 8 | | | Graft Failure-Free Survival Months since Transplant |
| 75 | GFSTSRVCENS | Num | 8 | INDF. | | Graft Failure-Free Survival Indicator |
| 76 | GFSTVENT | Char | 30 | | | Graft Failure-Free Survival Outcome |
| 77 | GFSDAY | Num | 8 | | | GVHD-Free Survival Days since Transplant |
| 78 | GFSMON | Num | 8 | | | GVHD-Free Survival Months since Transplant |
| 79 | GFSCENS | Num | 8 | INDF. | | GVHD-Free Survival Indicator |
| 80 | GFSEVENT | Char | 9 | | | GVHD-Free Survival Outcome (composite endpoint of survival without grade III-IV acute GVHD or any chronic GVHD) |
| 81 | PCS_N014 | Num | 8 | | | Baseline SF-36 Physical Component Score |
| 82 | PCS_0100 | Num | 8 | | | Day 100 SF-36 Physical Component Score |
| 83 | PCS_0180 | Num | 8 | | | Day 180 SF-36 Physical Component Score |
| 84 | PCS_0365 | Num | 8 | | | One Year SF-36 Physical Component Score |
| 85 | MCS_N014 | Num | 8 | | | Baseline SF-36 Mental Component Score |
| 86 | MCS_0100 | Num | 8 | | | Day 100 SF-36 Mental Component Score |
| 87 | MCS_0180 | Num | 8 | | | Day 180 SF-36 Mental Component Score |
| 88 | MCS_0365 | Num | 8 | | | One Year SF-36 Mental Component Score |
| 89 | PQL_N014 | Num | 8 | | | Baseline Pediatric QL Score |
| 90 | PQL_0100 | Num | 8 | | | Day 100 Pediatric QL Score |
| 91 | PQL_0180 | Num | 8 | | | Day 180 Pediatric QL Score |
| 92 | PQL_0365 | Num | 8 | | | One Year Pediatric QL Score |
| 93 | ENRLDATE_DAYS | Num | 8 | | | Enrollment Date (recode: number of days after consent) |
| 94 | DATE_OF_DIAGNOSIS_DAYS | Num | 8 | | | Diagnosis Date (recode: number of days after consent) |
| 95 | CONDNGDT_DAYS | Num | 8 | | | Conditioning Regimen Start Date (recode: number of days after consent) |
| 96 | TXDTPXP_DAYS | Num | 8 | | | Transplant Date (recode: number of days after consent) |
| 97 | FUDATE_DAYS | Num | 8 | | | Last Contact Date from Emmes data source (recode: number of days after consent) |
| 98 | PGFDT_DAYS | Num | 8 | | | Primary Graft Failure Date (Recoded Based on ERC adjudication on primary graft failure) (recode: number of days after consent) |
| 99 | SGFDT_DAYS | Num | 8 | | | ERC-adjudicated Date of Secondary Graft Failure (recode: number of days after consent) |
| 100 | GFDT_DAYS | Num | 8 | | | Graft Failure Date (Based on ERC) (recode: number of days after consent) |
| 101 | STAGEDT_234_DAYS | Num | 8 | | | First Date of Grades II, III, or IV aGVHD (recode: number of days after consent) |
| 102 | STAGEDT_34_DAYS | Num | 8 | | | First Date of Grades III or IV aGVHD (recode: number of days after consent) |
| 103 | FGCGDGDGT_DAYS | Num | 8 | | | First Date of cGVHD diagnosis/onset (recode: number of days after consent) |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------------|------|-----|---------|----------|--|
| 104 | D1ANCDT_DAYS | Num | 8 | | | Site-reported ANC Recovery Date (recode: number of days after consent) |
| 105 | EBVDT_DAYS | Num | 8 | | | First Date of Epstein-Barr Virus (EBV) Infection (recode: number of days after consent) |
| 106 | CMVDT_DAYS | Num | 8 | | | First Date of Cytomegalovirus (CMV) Infection (recode: number of days after consent) |
| 107 | F22PTLDT_DAYS | Num | 8 | | | First Date of PTLT Diagnosis (recode: number of days after consent) |
| 108 | FUDATE_COMBINE_DAYS | Num | 8 | | | Emmes/CIBMTR Last Contact Date for longer follow-up beyond 1 year (recode: number of days after consent) |
| 109 | DTHDT_DAYS | Num | 8 | | | Death Date (recode: number of days after consent) |
| 110 | RACEG | Num | 8 | RACEGF. | | Race (grouped: 1=White, 2=Black, 3 = Asian/Pacific Islander, 9=Other/Unknown/Missing) |
| 111 | DONOR_RACEG | Char | 22 | | | DonorRace (regrouped) |

Data Set Name: pcg.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|------------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | PCGSKIN | Char | 1 | \$X18312X. | \$1. | PCG Skin Score |
| 6 | PCGMOUTH | Char | 1 | \$X18334X. | \$1. | PCG Mouth Score |
| 7 | PCGGITRC | Char | 1 | \$X18350X. | \$1. | PCG GI Tract Score |
| 8 | PCGEYE | Char | 1 | \$X18354X. | \$1. | PCG Eye Score |
| 9 | PCGJOINT | Char | 1 | \$X28972X. | \$1. | PCG Joint / Fascia Score |
| 10 | PCGNOEXM | Char | 1 | \$X29029X. | \$1. | PCG No GYN Exam |
| 11 | PCGGNITL | Char | 1 | \$X18356X. | \$1. | PCG Genital Tract Score |
| 12 | PCGLUNG | Char | 1 | \$X18358X. | \$1. | PCG Lung Score |
| 13 | PCGSEV1 | Char | 1 | \$X19005X. | \$1. | PCG Severity Scale 1 |
| 14 | PCGSEV2 | Char | 2 | \$X28973X. | \$2. | PCG Severity Scale 2 |
| 15 | PCGRASH | Char | 1 | \$X1457X. | \$1. | PCG Eryth/Maculopap Rash |
| 16 | PCGVOMIT | Char | 1 | \$X1457X. | \$1. | PCG Nausea, Vomit, Diarrh |
| 17 | PCGLIVER | Char | 1 | \$X28962X. | \$1. | PCG Liver Score |
| 18 | PCGFEV1 | Num | 8 | 4. | 4. | PCG FEV1 |
| 19 | PCGFEVND | Char | 1 | \$X28970X. | \$1. | PCG FEV1 Not Done |
| 20 | PCGDLCO | Num | 8 | 4. | 4. | PCG DLCOc |
| 21 | PCGDLCND | Char | 1 | \$X28970X. | \$1. | PCG DLCOc Not Done |
| 22 | PCGDATE_DAYS | Num | 8 | | | PCG Date of Visit (recode: number of days after consent) |
| 23 | PCGLFTDT_DAYS | Num | 8 | | | PCG LFT Sample Date (recode: number of days after consent) |
| 24 | PCGFEVDT_DAYS | Num | 8 | | | PCG Date of FEV1 (recode: number of days after consent) |
| 25 | PCGDLCDT_DAYS | Num | 8 | | | PCG Date of DLCOc (recode: number of days after consent) |

Data Set Name: pdr.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|--------------|------|-----|------------|----------|---|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | PDSEQNUM | Char | 2 | \$XPDSEQX. | \$2. | Deviation/Violation Num |
| 5 | PDREVSUM | Char | 551 | \$551. | \$2000. | Event Summary |
| 6 | PDRQUAL | Char | 1 | \$X1457X. | \$1. | Event Qualification |
| 7 | PDRCATEG | Char | 11 | \$X41403X. | \$11. | Deviation Category |
| 8 | PDRCATSP | Char | 40 | \$40. | \$40. | Category Other Specify |
| 9 | PDRREASN | Char | 10 | \$X41406X. | \$10. | Reason For Deviation |
| 10 | PDRRSNSP | Char | 40 | \$40. | \$40. | Reason Other Specify |
| 11 | PDRDSMB | Char | 1 | \$X1457X. | \$1. | DSMB Reportable |
| 12 | PDRDSMSF | Char | 2 | \$X43909X. | \$2. | DSMB Spring Fall |
| 13 | PDRDSMYR | Num | 8 | 5. | 5. | DSMB Year |
| 14 | PDRCCCPR | Char | 1 | \$X1457X. | \$1. | Center Perform Report |
| 15 | PDRCAPA | Char | 1 | \$X1457X. | \$1. | Site Re-training CAPA |
| 16 | PDRCAPSP | Char | 270 | \$270. | \$2000. | CAPA Specify |
| 17 | PDRRECOM | Char | 1 | \$X1457X. | \$1. | Review Complete |
| 18 | PDRPDREV | Char | 1 | \$X1457X. | \$1. | Project Director Reviewed |
| 19 | PDRGMREV | Char | 1 | \$X1457X. | \$1. | Group Manager Reviewed |
| 20 | PDREVDT_DAYS | Num | 8 | | | Event Review Date (recode: number of days after consent) |
| 21 | PDDATE_DAYS | Num | 8 | | | Deviation/Violation Date (recode: number of days after consent) |

Data Set Name: pdv.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|------------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | PDSEQNUM | Char | 2 | \$XPDSEQX. | \$2. | Deviation/Violation Num |
| 5 | PDVCATEG | Char | 2 | \$X41403X. | \$2. | Deviation Category |
| 6 | PDVCATSP | Char | 50 | \$50. | \$50. | Deviation Categor Specify |
| 7 | PDVREASO | Char | 2 | \$X41406X. | \$2. | Deviation Reason |
| 8 | PDVREASP | Char | 50 | \$50. | \$50. | Deviation Reason Specify |
| 9 | PDVSTDIS | Char | 1 | \$X1457X. | \$1. | Deviation Therapy Discont |
| 10 | PDVIRBRE | Char | 1 | \$X1457X. | \$1. | Deviation IRB reported |
| 11 | PDVIRBOU | Char | 1 | \$X41572X. | \$1. | Deviation IRB outcome |
| 12 | PDVCORRC | Char | 1 | \$X1457X. | \$1. | Deviation Corrective Act |
| 13 | PDVIDTDT_DAYS | Num | 8 | | | Date Deviation Identified (recode: number of days after consent) |
| 14 | PDVIRBDT_DAYS | Num | 8 | | | Deviation IRB Report Date (recode: number of days after consent) |
| 15 | PDDATE_DAYS | Num | 8 | | | Deviation/Violation Date (recode: number of days after consent) |

Data Set Name: pql.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|----------|------|-----|------------|----------|---------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | PQLPTAGE | Char | 1 | \$X36519X. | \$1. | Patient Age |
| 6 | PQLACHE | Char | 2 | \$X36534X. | \$2. | Ache In Muscles |
| 7 | PQLHURT | Char | 2 | \$X36534X. | \$2. | Ache Or Hurt |
| 8 | PQLHURSP | Char | 50 | \$50. | \$50. | Ache Or Hurt Specify |
| 9 | PQLTIRED | Char | 2 | \$X36534X. | \$2. | Feel Tired |
| 10 | PQLWEAK | Char | 2 | \$X36534X. | \$2. | Feel Physically Weak |
| 11 | PQLHDSLP | Char | 2 | \$X36534X. | \$2. | Hard To Sleep |
| 12 | PQLSLOT | Char | 2 | \$X36534X. | \$2. | Sleep A Lot |
| 13 | PQLLIKE | Char | 2 | \$X36534X. | \$2. | Tired To Do Things I Like |
| 14 | PQLHVMED | Char | 2 | \$X36534X. | \$2. | Sick Have Med Treatment |
| 15 | PQLFOOD | Char | 2 | \$X36534X. | \$2. | Sick Foods and Smells |
| 16 | PQLTHINK | Char | 2 | \$X36534X. | \$2. | Sick Think Of Med Tx |
| 17 | PQLAPRCH | Char | 2 | \$X36534X. | \$2. | Sick Approached |
| 18 | PQLEFFCT | Char | 2 | \$X36534X. | \$2. | Worry Side Effects Med Tx |
| 19 | PQLWRKNG | Char | 2 | \$X36534X. | \$2. | Worry Med Tx Working |
| 20 | PQLHOSP | Char | 2 | \$X36534X. | \$2. | Scared When Go To Hosp |
| 21 | PQLINFXN | Char | 2 | \$X36534X. | \$2. | Scared Infections |
| 22 | PQLGROW | Char | 2 | \$X36534X. | \$2. | Worry Grow Properly |
| 23 | PQLNEEDL | Char | 2 | \$X36534X. | \$2. | Scared Needle Sticks |
| 24 | PQLCHILD | Char | 2 | \$X36534X. | \$2. | Think About Children |
| 25 | PQLRLPS | Char | 2 | \$X36534X. | \$2. | Worry Disease Relapse |
| 26 | PQLNORML | Char | 2 | \$X36534X. | \$2. | Worry Normal Life |
| 27 | PQLBODY | Char | 2 | \$X36534X. | \$2. | Body Looks Different |
| 28 | PQLWANT | Char | 2 | \$X36534X. | \$2. | Worry People Do Not Want |
| 29 | PQLPUBTY | Char | 2 | \$X36534X. | \$2. | Worry Reaching Puberty |
| 30 | PQLTASTE | Char | 2 | \$X36534X. | \$2. | Food Does Not Taste Good |
| 31 | PQLHUNGR | Char | 2 | \$X36534X. | \$2. | Not Hungry |
| 32 | PQLDRINK | Char | 2 | \$X36534X. | \$2. | Drink A Lot When Chewing |
| 33 | PQLCONST | Char | 2 | \$X36534X. | \$2. | Have Constipation |
| 34 | PQLDIARR | Char | 2 | \$X36534X. | \$2. | Have Diarrhea |
| 35 | PQLHEARD | Char | 2 | \$X36534X. | \$2. | Remember Things Heard |
| 36 | PQLBOTHR | Char | 2 | \$X36534X. | \$2. | Something Bothers Me |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|------------|------|-----|------------|----------|---|
| 37 | PQLATTN | Char | 2 | \$X36534X. | \$2. | Keep Attention Long Time |
| 38 | PQLREAD | Char | 2 | \$X36534X. | \$2. | Remember Things Read |
| 39 | PQLASKQ | Char | 2 | \$X36534X. | \$2. | Hard To Ask Questions |
| 40 | PQLTELL | Char | 2 | \$X36534X. | \$2. | Hard To Tell How I Feel |
| 41 | PQLTALK | Char | 2 | \$X36534X. | \$2. | Hard to Talk With Others |
| 42 | PQLPRURI | Char | 2 | \$X36534X. | \$2. | Have Pruritis |
| 43 | PQLSKIN | Char | 2 | \$X36534X. | \$2. | Have Skin Infections |
| 44 | PQLDRMTH | Char | 2 | \$X36534X. | \$2. | Have Dry Mouth |
| 45 | PQLEYE | Char | 2 | \$X36534X. | \$2. | Have Dry Or Burning Eyes |
| 46 | PQLLONE | Char | 2 | \$X36534X. | \$2. | Feel Lonely |
| 47 | PQLSOB | Char | 2 | \$X36534X. | \$2. | Short of Breath |
| 48 | PQLDT_DAYS | Num | 8 | | | Date Of Assessment (recode: number of days after consent) |

Data Set Name: s18.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | S18BDCD1 | Char | 1 | \$X1457X. | \$1. | Blood Drawn Completion D1 |
| 6 | S18ST1TM | Char | 5 | \$5. | \$5. | Blood Sample 1 Start Time |
| 7 | S18SP1TM | Char | 5 | \$5. | \$5. | Blood Sample 1 End Time |
| 8 | S18BS1TM | Char | 5 | \$5. | \$5. | Blood Sample 1 Time |
| 9 | S18BDPD2 | Char | 1 | \$X1457X. | \$1. | Blood Drawn Prior to D2 |
| 10 | S18BS2TM | Char | 5 | \$5. | \$5. | Blood Sample 2 Time |
| 11 | S18BDCD2 | Char | 1 | \$X1457X. | \$1. | Blood Drawn Completion D2 |
| 12 | S18ST3TM | Char | 5 | \$5. | \$5. | Blood Sample 3 Start Time |
| 13 | S18SP3TM | Char | 5 | \$5. | \$5. | Blood Sample 3 End Time |
| 14 | S18BS3TM | Char | 5 | \$5. | \$5. | Blood Sample 3 Time |
| 15 | S18BDCD3 | Char | 1 | \$X1457X. | \$1. | Blood Drawn Completion D3 |
| 16 | S18ST4TM | Char | 5 | \$5. | \$5. | Blood Sample 4 Start Time |
| 17 | S18SP4TM | Char | 5 | \$5. | \$5. | Blood Sample 4 End Time |
| 18 | S18BS4TM | Char | 5 | \$5. | \$5. | Blood Sample 4 Time |
| 19 | S18BDD00 | Char | 1 | \$X1457X. | \$1. | Blood Drawn Day 0 |
| 20 | S18LYMPH | Num | 8 | 5.1 | 5.1 | Absolute Lymphocyte Count |
| 21 | S18BS5TM | Char | 5 | \$5. | \$5. | Blood Sample 5 Time |
| 22 | S18BDD07 | Char | 1 | \$X1457X. | \$1. | Blood Drawn Day 7 |
| 23 | S18BS6TM | Char | 5 | \$5. | \$5. | Blood Sample 6 Time |
| 24 | S18BDPC1 | Char | 1 | \$X1457X. | \$1. | Blood Drawn Pre Cond 1 |
| 25 | S18BDDON | Char | 1 | \$X1457X. | \$1. | Blood Drawn From Donor |
| 26 | S18BDPC2 | Char | 1 | \$X1457X. | \$1. | Blood Drawn Pre Cond 2 |
| 27 | S18S1DT_DAYS | Num | 8 | | | Blood Sample 1 Start Date (recode: number of days after consent) |
| 28 | S18E1DT_DAYS | Num | 8 | | | Blood Sample 1 End Date (recode: number of days after consent) |
| 29 | S18BS1DT_DAYS | Num | 8 | | | Blood Sample 1 Date (recode: number of days after consent) |
| 30 | S18BS2DT_DAYS | Num | 8 | | | Blood Sample 2 Date (recode: number of days after consent) |
| 31 | S18S3DT_DAYS | Num | 8 | | | Blood Sample 3 Start Date (recode: number of days after consent) |
| 32 | S18E3DT_DAYS | Num | 8 | | | Blood Sample 3 End Date (recode: number of days after consent) |
| 33 | S18BS3DT_DAYS | Num | 8 | | | Blood Sample 3 Date (recode: number of days after consent) |
| 34 | S18S4DT_DAYS | Num | 8 | | | Blood Sample 4 Start Date (recode: number of days after consent) |
| 35 | S18E4DT_DAYS | Num | 8 | | | Blood Sample 4 End Date (recode: number of days after consent) |
| 36 | S18BS4DT_DAYS | Num | 8 | | | Blood Sample 4 Date (recode: number of days after consent) |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|--------|----------|--|
| 37 | S18BS5DT_DAYS | Num | 8 | | | Blood Sample 5 Date (recode: number of days after consent) |
| 38 | S18BS6DT_DAYS | Num | 8 | | | Blood Sample 6 Date (recode: number of days after consent) |
| 39 | S18BS7DT_DAYS | Num | 8 | | | Blood Sample 7 Date (recode: number of days after consent) |
| 40 | S18BS8DT_DAYS | Num | 8 | | | Blood Sample 8 Date (recode: number of days after consent) |
| 41 | S18BS9DT_DAYS | Num | 8 | | | Blood Sample 9 Date (recode: number of days after consent) |

Data Set Name: sfh.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|------------|-----------------|-------------|------------|---------------|-----------------|---------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | GENHLTH | Char | 1 | \$X3667X. | \$1. | 1. General health |
| 6 | COMPARE | Char | 1 | \$X3668X. | \$1. | 2. Compare to a year ago |
| 7 | VIGOROUS | Char | 1 | \$X3677X. | \$1. | 3a. Vigorous activities |
| 8 | MODERATE | Char | 1 | \$X3677X. | \$1. | 3b. Moderate activities |
| 9 | LIFTING | Char | 1 | \$X3677X. | \$1. | 3c. Lifting groceries |
| 10 | CLINBSEV | Char | 1 | \$X3677X. | \$1. | 3d. Climbing several flig |
| 11 | CLIMBONE | Char | 1 | \$X3677X. | \$1. | 3e. Climbing one flight |
| 12 | BENDING | Char | 1 | \$X3677X. | \$1. | 3f. Bending or kneeling |
| 13 | WALKMILE | Char | 1 | \$X3677X. | \$1. | 3g. Walking more than mi |
| 14 | WALKSBLK | Char | 1 | \$X3677X. | \$1. | 3h. Walk several blocks |
| 15 | WALK1BLK | Char | 1 | \$X3677X. | \$1. | 3i. Walk one block |
| 16 | BATHING | Char | 1 | \$X3677X. | \$1. | 3j. Bathing or dressing |
| 17 | CUTTME | Char | 1 | \$X5712X. | \$1. | 4a. Time cut down |
| 18 | LESSACC | Char | 1 | \$X5712X. | \$1. | 4b. Less accomplished |
| 19 | WORKLMT | Char | 1 | \$X5712X. | \$1. | 4c. Work limited |
| 20 | PRFMDIFF | Char | 1 | \$X5712X. | \$1. | 4d. Perform difficulty |
| 21 | ECUTTME | Char | 1 | \$X5712X. | \$1. | 5a. Emotion time cut down |
| 22 | ELESSACC | Char | 1 | \$X5712X. | \$1. | 5b. Emotion less accompl |
| 23 | ECARELES | Char | 1 | \$X5712X. | \$1. | 5c. Emot less careful |
| 24 | INTERFER | Char | 1 | \$X3669X. | \$1. | 6. Interefere with normal |
| 25 | BODYPAIN | Char | 1 | \$X3670X. | \$1. | 7. Bodily pain |
| 26 | WORKPAIN | Char | 1 | \$X3671X. | \$1. | 8. Pain interfere work |
| 27 | FULLLIFE | Char | 1 | \$X5712X. | \$1. | 9a. Full of life |
| 28 | FEELNERV | Char | 1 | \$X5712X. | \$1. | 9b. Feel nervous |
| 29 | FEELDOWN | Char | 1 | \$X5712X. | \$1. | 9c. Feel down in dumps |
| 30 | FEELCALM | Char | 1 | \$X5712X. | \$1. | 9d. Feel calm |
| 31 | FLEENERGY | Char | 1 | \$X5712X. | \$1. | 9e. Feel a lot of energy |
| 32 | FEELDEPR | Char | 1 | \$X5712X. | \$1. | 9f. Feel depressed |
| 33 | FEELWORN | Char | 1 | \$X5712X. | \$1. | 9g. Feel worn/washed out |
| 34 | FEELHAP | Char | 1 | \$X5712X. | \$1. | 9h. Feel happy/cheerful |
| 35 | FEELTIR | Char | 1 | \$X5712X. | \$1. | 9i. Feel tired/fatigued |
| 36 | INSOCIAL | Char | 1 | \$X5712X. | \$1. | Interfere social activity |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|---|
| 37 | SICKEASY | Char | 1 | \$X3673X. | \$1. | 11a. Sick easier |
| 38 | HEALTHY | Char | 1 | \$X3673X. | \$1. | 11b. Healthy as anybody |
| 39 | WORSE | Char | 1 | \$X3673X. | \$1. | 11c. Expecting worse |
| 40 | EXCLNT | Char | 1 | \$X3673X. | \$1. | 11d. Health is excellent |
| 41 | SF36DATE_DAYS | Num | 8 | | | Date SF-36 Performed (recode: number of days after consent) |

Data Set Name: *sgf.sas7bdat*

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|---|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | DECANC | Char | 1 | \$X1457X. | \$1. | Decline in ANC |
| 5 | ANC1SGF | Num | 8 | 4. | 4. | ANC Day 1 |
| 6 | ANC2SGF | Num | 8 | 4. | 4. | ANC Day 2 |
| 7 | ANC3SGF | Num | 8 | 4. | 4. | ANC Day 3 |
| 8 | GFGIVEN | Char | 1 | \$X1457X. | \$1. | Growth Factor Given |
| 9 | RSPNDGF | Char | 1 | \$X1457X. | \$1. | Respond to Growth Factor |
| 10 | CHIMASSY | Char | 1 | \$X1457X. | \$1. | Chimerism Assay |
| 11 | CHIMMTHD | Char | 1 | \$X1500X. | \$1. | Evaluation Method |
| 12 | CHIMTYPE | Char | 1 | \$X4470X. | \$1. | Chimerism Sample Type |
| 13 | CHIMRESU | Char | 1 | \$X1522X. | \$1. | Assay Results |
| 14 | PCTDONOR | Num | 8 | 3. | 3. | Chimerism Percent Donor |
| 15 | SECNDHCT | Char | 1 | \$X1457X. | \$1. | Second HCT |
| 16 | SECHCTGF | Char | 1 | \$X1457X. | \$1. | 2nd HCT For Graft Failure |
| 17 | DLIGIVEN | Char | 1 | \$X1457X. | \$1. | DLI Given |
| 18 | ANC1SGDT_DAYS | Num | 8 | | | ANC Day 1 Date (recode: number of days after consent) |
| 19 | ANC2SGDT_DAYS | Num | 8 | | | ANC Day 2 Date (recode: number of days after consent) |
| 20 | ANC3SGDT_DAYS | Num | 8 | | | ANC Day 3 Date (recode: number of days after consent) |
| 21 | CHIMAYDT_DAYS | Num | 8 | | | Chimerism Assay Date (recode: number of days after consent) |
| 22 | SECHCTDT_DAYS | Num | 8 | | | Second HCT Date (recode: number of days after consent) |

Data Set Name: t28.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|------------|-----------------|-------------|------------|---------------|-----------------|---------------------------|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | TXFEVER | Char | 1 | \$X18341X. | \$1. | Fever |
| 6 | INFRLRXN | Char | 1 | \$X24060X. | \$1. | Infusion Related Reaction |
| 7 | ALRGCRXN | Char | 1 | \$X24060X. | \$1. | Allergic Reaction |
| 8 | ANAPHYLX | Char | 1 | \$X24062X. | \$1. | Anaphylaxis |
| 9 | MUCOSITI | Char | 1 | \$X43608X. | \$1. | GI Mucositis |
| 10 | TXNAUSEA | Char | 1 | \$X23126X. | \$1. | Nausea |
| 11 | VOMIT | Char | 1 | \$X23124X. | \$1. | Vomiting |
| 12 | DIARRHEA | Char | 1 | \$X23127X. | \$1. | Diarrhea |
| 13 | CYSTNINF | Char | 1 | \$X23113X. | \$1. | Cystitis Noninfective |
| 14 | ACKIDINJ | Char | 1 | \$X23859X. | \$1. | Acute Kidney Injury |
| 15 | CHKIDDIS | Char | 1 | \$X24063X. | \$1. | Chronic Kidney Disease |
| 16 | RCVDIALY | Char | 1 | \$X1457X. | \$1. | Receive Dialysis |
| 17 | LBVALCOR | Char | 1 | \$X1457X. | \$1. | Lab Values Corrected |
| 18 | HEMORRHG | Char | 1 | \$X23114X. | \$1. | Hemorrhage |
| 19 | ORGSYHEM | Char | 1 | \$X18324X. | \$1. | Organ System Hemorrhage |
| 20 | ORGSYHSP | Char | 50 | \$50. | \$50. | Organ System Hem Spec |
| 21 | HYPOTEN | Char | 1 | \$X23106X. | \$1. | Hypotension |
| 22 | HYPERTSN | Char | 1 | \$X23115X. | \$1. | Hypertension |
| 23 | CRDARRHY | Char | 1 | \$X23116X. | \$1. | Cardiac Arrhythmia |
| 24 | CRDARRSP | Char | 50 | \$50. | \$50. | Cardiac Arrhythmia Specif |
| 25 | MYOCDINF | Char | 1 | \$X24064X. | \$1. | Myocardial Infarction |
| 26 | LFVTSYDF | Char | 1 | \$X23107X. | \$1. | Left Vent Syst Dysfunct |
| 27 | PERCRDEF | Char | 1 | \$X23117X. | \$1. | Pericardial Effusion |
| 28 | RSTCDMYP | Char | 1 | \$X23118X. | \$1. | Restrictive Cardiomyopath |
| 29 | SOMNOLN | Char | 1 | \$X23119X. | \$1. | Somnolence |
| 30 | TXSEIZR | Char | 1 | \$X23108X. | \$1. | Seizure |
| 31 | NEURPTHY | Char | 1 | \$X24065X. | \$1. | Neuropathy |
| 32 | THRMBPUR | Char | 1 | \$X23120X. | \$1. | Thrombocytopenic Purpura |
| 33 | CAPLKSYN | Char | 1 | \$X23121X. | \$1. | Capillary Leak Syndrome |
| 34 | THROMBEV | Char | 1 | \$X24078X. | \$1. | Thromboembolic Event |
| 35 | AVASCNEC | Char | 1 | \$X24074X. | \$1. | Avascular Necrosis |
| 36 | OSTEOPOR | Char | 1 | \$X24075X. | \$1. | Osteoporosis |

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|------------|----------|---|
| 37 | TXHYPXIA | Char | 1 | \$X23104X. | \$1. | Hypoxia |
| 38 | TXDYSYNA | Char | 1 | \$X23109X. | \$1. | Dyspnea |
| 39 | HYPRGLYC | Char | 1 | \$X24071X. | \$1. | Hyperglycemia |
| 40 | CHOLESTR | Char | 1 | \$X24072X. | \$1. | Cholesterol |
| 41 | TRIGLYCR | Char | 1 | \$X24073X. | \$1. | Triglycerides |
| 42 | TXALT | Char | 1 | \$X5545X. | \$1. | ALT |
| 43 | TXAST | Char | 1 | \$X11753X. | \$1. | AST |
| 44 | TXBILIRB | Char | 1 | \$X3854X. | \$1. | Bilirubin |
| 45 | TXALKPH | Char | 1 | \$X3855X. | \$1. | Alkaline Phosphatase |
| 46 | TXJAUND | Char | 1 | \$X1457X. | \$1. | Jaundice |
| 47 | HEPTMGLY | Char | 1 | \$X1457X. | \$1. | Hepatomegaly |
| 48 | RTQUADPN | Char | 1 | \$X1457X. | \$1. | Right Upper Quadrant Pain |
| 49 | TXWGHTGN | Char | 1 | \$X1457X. | \$1. | Weight Gain >5 Percent |
| 50 | VODETIOL | Char | 1 | \$X1457X. | \$1. | VOD Etiology |
| 51 | GVHETIOL | Char | 1 | \$X1457X. | \$1. | GVHD Etiology |
| 52 | GVHBIOP | Char | 1 | \$X1822X. | \$1. | GVHD Biopsy |
| 53 | GVHDOPP | Char | 1 | \$X4472X. | \$1. | GVHD Doppler |
| 54 | INFETIOL | Char | 1 | \$X1457X. | \$1. | Infection Etiology |
| 55 | OTHETIOL | Char | 1 | \$X1457X. | \$1. | Other Etiology |
| 56 | OTHBIOP | Char | 1 | \$X1822X. | \$1. | Other Biopsy |
| 57 | OTHDOPP | Char | 1 | \$X4472X. | \$1. | Other Doppler |
| 58 | UNKETIOL | Char | 1 | \$X1457X. | \$1. | Unknown Etiology |
| 59 | OTHETSP | Char | 50 | \$50. | \$50. | Other Etiology Specify |
| 60 | TXYEVLDT_DAYS | Num | 8 | | | Toxicity Evaluation Date (recode: number of days after consent) |

Data Set Name: txp.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|-----------|----------|--|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | PTWGTTB | Num | 8 | 7.1 | 7.1 | Patient Weight Segment B |
| 6 | TNCCTINF | Num | 8 | 8.2 | 8.2 | TNC Count Infused |
| 7 | CDCNTINF | Num | 8 | 9.2 | 9.2 | CD34 Count Infused |
| 8 | CMVSTAT | Char | 1 | \$X1579X. | \$1. | CMV Status |
| 9 | TXDTPX_DAYS | Num | 8 | | | Stem Cell Infusion Date (recode: number of days after consent) |
| 10 | CONDNGDT_DAYS | Num | 8 | | | Conditioning Date (recode: number of days after consent) |

Data Set Name: vdf.sas7bdat

| Num | Variable | Type | Len | Format | Informat | Label |
|-----|---------------|------|-----|------------|----------|---|
| 1 | ANONID | Char | 7 | | | Randomized Subject ID |
| 2 | PROT | Char | 5 | \$5. | \$5. | Protocol |
| 3 | PROTSEG | Char | 1 | \$1. | \$1. | Segment |
| 4 | VISNO | Char | 4 | \$4. | \$4. | VISNO |
| 5 | VDFOCCUR | Char | 1 | \$X1457X. | \$1. | Visit Occur |
| 6 | VDFVSTYP | Char | 1 | \$X55832X. | \$1. | Visit Type |
| 7 | VDFDELAY | Char | 1 | \$X1457X. | \$1. | Visit Delay |
| 8 | VDFDLYRS | Char | 2 | \$X56403X. | \$2. | Visit Delay Reason |
| 9 | VDFREAS | Char | 2 | \$X55870X. | \$2. | No Visit Reason |
| 10 | VDFVISDT_DAYS | Num | 8 | | | Visit Date (recode: number of days after consent) |